A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.
Tumors or cancer of the LIVER.
A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm but is often wrongly used as a synonym for "cancer." (From Dorland, 27th ed)
A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)
The first alpha-globulins to appear in mammalian sera during FETAL DEVELOPMENT and the dominant serum proteins in early embryonic life.
A lesion with cytological characteristics associated with invasive carcinoma but the tumor cells are confined to the epithelium of origin, without invasion of the basement membrane.
Administration of antineoplastic agents together with an embolizing vehicle. This allows slow release of the agent as well as obstruction of the blood supply to the neoplasm.
A malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. (Stedman, 25th ed)
A benign epithelial tumor of the LIVER.
Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.
Experimentally induced tumors of the LIVER.
A cell line derived from cultured tumor cells.
Histochemical localization of immunoreactive substances using labeled antibodies as reagents.
Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.
Excision of all or part of the liver. (Dorland, 28th ed)
A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances.
An invasive (infiltrating) CARCINOMA of the mammary ductal system (MAMMARY GLANDS) in the human BREAST.
Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue.
A malignant skin neoplasm that seldom metastasizes but has potentialities for local invasion and destruction. Clinically it is divided into types: nodular, cicatricial, morphaic, and erythematoid (pagetoid). They develop on hair-bearing skin, most commonly on sun-exposed areas. Approximately 85% are found on the head and neck area and the remaining 15% on the trunk and limbs. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1471)
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
A human liver tumor cell line used to study a variety of liver-specific metabolic functions.
Ability of neoplasms to infiltrate and actively destroy surrounding tissue.
Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS.
Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.
The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.
A preparation of oil that contains covalently bound IODINE. It is commonly used as a RADIOCONTRAST AGENT and as a suspension medium for CHEMOTHERAPEUTIC AGENTS.
Malignant neoplasm arising from the epithelium of the BRONCHI. It represents a large group of epithelial lung malignancies which can be divided into two clinical groups: SMALL CELL LUNG CANCER and NON-SMALL-CELL LUNG CARCINOMA.
A noninvasive (noninfiltrating) carcinoma of the breast characterized by a proliferation of malignant epithelial cells confined to the mammary ducts or lobules, without light-microscopy evidence of invasion through the basement membrane into the surrounding stroma.
A malignant epithelial tumor with a glandular organization.
Carcinoma characterized by bands or cylinders of hyalinized or mucinous stroma separating or surrounded by nests or cords of small epithelial cells. When the cylinders occur within masses of epithelial cells, they give the tissue a perforated, sievelike, or cribriform appearance. Such tumors occur in the mammary glands, the mucous glands of the upper and lower respiratory tract, and the salivary glands. They are malignant but slow-growing, and tend to spread locally via the nerves. (Dorland, 27th ed)
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Compounds that include the amino-N-phenylamide structure.
An important compound functioning as a component of the coenzyme NAD. Its primary significance is in the prevention and/or cure of blacktongue and PELLAGRA. Most animals cannot manufacture this compound in amounts sufficient to prevent nutritional deficiency and it therefore must be supplemented through dietary intake.
An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses.
A carcinoma composed mainly of epithelial elements with little or no stroma. Medullary carcinomas of the breast constitute 5%-7% of all mammary carcinomas; medullary carcinomas of the thyroid comprise 3%-10% of all thyroid malignancies. (From Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1141; Segen, Dictionary of Modern Medicine, 1992)
Substances that inhibit or prevent the proliferation of NEOPLASMS.
INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact.
A infiltrating (invasive) breast cancer, relatively uncommon, accounting for only 5%-10% of breast tumors in most series. It is often an area of ill-defined thickening in the breast, in contrast to the dominant lump characteristic of ductal carcinoma. It is typically composed of small cells in a linear arrangement with a tendency to grow around ducts and lobules. There is likelihood of axillary nodal involvement with metastasis to meningeal and serosal surfaces. (DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1205)
The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.
The transference of a part of or an entire liver from one human or animal to another.
All of the processes involved in increasing CELL NUMBER including CELL DIVISION.
RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.
Tumors or cancer of the LUNG.
Organic salts and esters of benzenesulfonic acid.
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
A group of carcinomas which share a characteristic morphology, often being composed of clusters and trabecular sheets of round "blue cells", granular chromatin, and an attenuated rim of poorly demarcated cytoplasm. Neuroendocrine tumors include carcinoids, small ("oat") cell carcinomas, medullary carcinoma of the thyroid, Merkel cell tumor, cutaneous neuroendocrine carcinoma, pancreatic islet cell tumors, and pheochromocytoma. Neurosecretory granules are found within the tumor cells. (Segen, Dictionary of Modern Medicine, 1992)
The type species of the genus ORTHOHEPADNAVIRUS which causes human HEPATITIS B and is also apparently a causal agent in human HEPATOCELLULAR CARCINOMA. The Dane particle is an intact hepatitis virion, named after its discoverer. Non-infectious spherical and tubular particles are also seen in the serum.
Tumors or cancer of the THYROID GLAND.
Tumors or cancer of the NASOPHARYNX.
Tumors or cancer of the human BREAST.
Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.
One of the mechanisms by which CELL DEATH occurs (compare with NECROSIS and AUTOPHAGOCYTOSIS). Apoptosis is the mechanism responsible for the physiological deletion of cells and appears to be intrinsically programmed. It is characterized by distinctive morphologic changes in the nucleus and cytoplasm, chromatin cleavage at regularly spaced sites, and the endonucleolytic cleavage of genomic DNA; (DNA FRAGMENTATION); at internucleosomal sites. This mode of cell death serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth.
A family of GLYCOSYLPHOSPHATIDYLINOSITOL-anchored, cell-surface heparan sulfate proteoglycans that may play a role in CELL GROWTH PROCESSES and CELL DIFFERENTIATION by modulating ligand-receptor interactions.
The main structural component of the LIVER. They are specialized EPITHELIAL CELLS that are organized into interconnected plates called lobules.
A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
A nitrosamine derivative with alkylating, carcinogenic, and mutagenic properties.
A variation of the PCR technique in which cDNA is made from RNA via reverse transcription. The resultant cDNA is then amplified using standard PCR protocols.
The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.
DNA present in neoplastic tissue.
Pathological processes of the LIVER.
INFLAMMATION of the LIVER in humans caused by HEPATITIS B VIRUS lasting six months or more. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact.
Tomography using x-ray transmission and a computer algorithm to reconstruct the image.
Pathological processes that tend eventually to become malignant. (From Dorland, 27th ed)
Experimental transplantation of neoplasms in laboratory animals for research purposes.
A tumor of both low- and high-grade malignancy. The low-grade grow slowly, appear in any age group, and are readily cured by excision. The high-grade behave aggressively, widely infiltrate the salivary gland and produce lymph node and distant metastases. Mucoepidermoid carcinomas account for about 21% of the malignant tumors of the parotid gland and 10% of the sublingual gland. They are the most common malignant tumor of the parotid. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p575; Holland et al., Cancer Medicine, 3d ed, p1240)
A mixed adenocarcinoma and squamous cell or epidermoid carcinoma.
Elements of limited time intervals, contributing to particular results or situations.
Ethyl ester of iodinated fatty acid of poppyseed oil. It contains 37% organically bound iodine and has been used as a diagnostic aid (radiopaque medium) and as an antineoplastic agent when part of the iodine is 131-I. (From Merck Index, 11th ed)
Immunologic techniques based on the use of: (1) enzyme-antibody conjugates; (2) enzyme-antigen conjugates; (3) antienzyme antibody followed by its homologous enzyme; or (4) enzyme-antienzyme complexes. These are used histologically for visualizing or labeling tissue specimens.
Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system.
An adenocarcinoma characterized by the presence of cells resembling the glandular cells of the ENDOMETRIUM. It is a common histological type of ovarian CARCINOMA and ENDOMETRIAL CARCINOMA. There is a high frequency of co-occurrence of this form of adenocarcinoma in both tissues.
Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)
Tumors or cancer of the ESOPHAGUS.
A nonparametric method of compiling LIFE TABLES or survival tables. It combines calculated probabilities of survival and estimates to allow for observations occurring beyond a measurement threshold, which are assumed to occur randomly. Time intervals are defined as ending each time an event occurs and are therefore unequal. (From Last, A Dictionary of Epidemiology, 1995)
Two or more abnormal growths of tissue occurring simultaneously and presumed to be of separate origin. The neoplasms may be histologically the same or different, and may be found in the same or different sites.
A highly malignant, primitive form of carcinoma, probably of germinal cell or teratomatous derivation, usually arising in a gonad and rarely in other sites. It is rare in the female ovary, but in the male it accounts for 20% of all testicular tumors. (From Dorland, 27th ed & Holland et al., Cancer Medicine, 3d ed, p1595)
Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.
Tumors or cancer of the COLON.
Nuclear phosphoprotein encoded by the p53 gene (GENES, P53) whose normal function is to control CELL PROLIFERATION and APOPTOSIS. A mutant or absent p53 protein has been found in LEUKEMIA; OSTEOSARCOMA; LUNG CANCER; and COLORECTAL CANCER.
Tumors or cancer of the MOUTH.
A carcinoma arising from MERKEL CELLS located in the basal layer of the epidermis and occurring most commonly as a primary neuroendocrine carcinoma of the skin. Merkel cells are tactile cells of neuroectodermal origin and histologically show neurosecretory granules. The skin of the head and neck are a common site of Merkel cell carcinoma, occurring generally in elderly patients. (Holland et al., Cancer Medicine, 3d ed, p1245)
INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally, and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown.
Malignant neoplasms involving the ductal systems of any of a number of organs, such as the MAMMARY GLANDS, the PANCREAS, the PROSTATE, or the LACRIMAL GLAND.
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
A short thick vein formed by union of the superior mesenteric vein and the splenic vein.
Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
Tumors or cancer of the STOMACH.
The total amount (cell number, weight, size or volume) of tumor cells or tissue in the body.
Solitary or multiple benign hepatic vascular tumors, usually occurring in women of 20-50 years of age. The nodule, poorly encapsulated, consists of a central stellate fibrous scar and normal liver elements such as HEPATOCYTES, small BILE DUCTS, and KUPFFER CELLS among the intervening fibrous septa. The pale colored central scar represents large blood vessels with hyperplastic fibromuscular layer and narrowing lumen.
A malignant neoplasm of the ADRENAL CORTEX. Adrenocortical carcinomas are unencapsulated anaplastic (ANAPLASIA) masses sometimes exceeding 20 cm or 200 g. They are more likely to be functional than nonfunctional, and produce ADRENAL CORTEX HORMONES that may result in hypercortisolism (CUSHING SYNDROME); HYPERALDOSTERONISM; and/or VIRILISM.
A variant of well-differentiated epidermoid carcinoma that is most common in the oral cavity, but also occurs in the larynx, nasal cavity, esophagus, penis, anorectal region, vulva, vagina, uterine cervix, and skin, especially on the sole of the foot. Most intraoral cases occur in elderly male abusers of smokeless tobacco. The treatment is surgical resection. Radiotherapy is not indicated, as up to 30% treated with radiation become highly aggressive within six months. (Segen, Dictionary of Modern Medicine, 1992)
INFLAMMATION of the LIVER with ongoing hepatocellular injury for 6 months or more, characterized by NECROSIS of HEPATOCYTES and inflammatory cell (LEUKOCYTES) infiltration. Chronic hepatitis can be caused by viruses, medications, autoimmune diseases, and other unknown factors.
A malignant tumor arising from the epithelium of the BILE DUCTS.
Tumors or cancer of the BILE DUCTS.
A poorly differentiated adenocarcinoma in which the nucleus is pressed to one side by a cytoplasmic droplet of mucus. It usually arises in the gastrointestinal system.
Tumors or cancer of the URINARY BLADDER.
Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
Identification of proteins or peptides that have been electrophoretically separated by blot transferring from the electrophoresis gel to strips of nitrocellulose paper, followed by labeling with antibody probes.
An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.
A benign tumor of the intrahepatic bile ducts.
Tumors or cancer of the SKIN.
Death resulting from the presence of a disease in an individual, as shown by a single case report or a limited number of patients. This should be differentiated from DEATH, the physiological cessation of life and from MORTALITY, an epidemiological or statistical concept.
The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION.
The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.
Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.
Those hepatitis B antigens found on the surface of the Dane particle and on the 20 nm spherical and tubular particles. Several subspecificities of the surface antigen are known. These were formerly called the Australia antigen.
A potent hepatotoxic and hepatocarcinogenic mycotoxin produced by the Aspergillus flavus group of fungi. It is also mutagenic, teratogenic, and causes immunosuppression in animals. It is found as a contaminant in peanuts, cottonseed meal, corn, and other grains. The mycotoxin requires epoxidation to aflatoxin B1 2,3-oxide for activation. Microsomal monooxygenases biotransform the toxin to the less toxic metabolites aflatoxin M1 and Q1.
Tumor suppressor genes located on the short arm of human chromosome 17 and coding for the phosphoprotein p53.
The determination of the pattern of genes expressed at the level of GENETIC TRANSCRIPTION, under specific circumstances or in a specific cell.
RNA present in neoplastic tissue.
The simultaneous analysis of multiple samples of TISSUES or CELLS from BIOPSY or in vitro culture that have been arranged in an array format on slides or microchips.
The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.
A branch of the celiac artery that distributes to the stomach, pancreas, duodenum, liver, gallbladder, and greater omentum.
A tumor of undifferentiated (anaplastic) cells of large size. It is usually bronchogenic. (From Dorland, 27th ed)
A pathologic process consisting of the proliferation of blood vessels in abnormal tissues or in abnormal positions.
The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway.
Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included.
A negative regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins.
Removal and pathologic examination of specimens in the form of small pieces of tissue from the living body.
Studies which start with the identification of persons with a disease of interest and a control (comparison, referent) group without the disease. The relationship of an attribute to the disease is examined by comparing diseased and non-diseased persons with regard to the frequency or levels of the attribute in each group.
In vivo methods of screening investigative anticancer drugs, biologic response modifiers or radiotherapies. Human tumor tissue or cells are transplanted into mice or rats followed by tumor treatment regimens. A variety of outcomes are monitored to assess antitumor effectiveness.
Cancers or tumors of the LARYNX or any of its parts: the GLOTTIS; EPIGLOTTIS; LARYNGEAL CARTILAGES; LARYNGEAL MUSCLES; and VOCAL CORDS.
Transplantation between animals of different species.
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)
Tumors or cancer of the UTERINE CERVIX.
A positive regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins.
Removal of tissue with electrical current delivered via electrodes positioned at the distal end of a catheter. Energy sources are commonly direct current (DC-shock) or alternating current at radiofrequencies (usually 750 kHz). The technique is used most often to ablate the AV junction and/or accessory pathways in order to interrupt AV conduction and produce AV block in the treatment of various tachyarrhythmias.
INFLAMMATION of the LIVER.
INFLAMMATION of the LIVER in humans that is caused by HEPATITIS C VIRUS lasting six months or more. Chronic hepatitis C can lead to LIVER CIRRHOSIS.
Tumors or cancer of the gallbladder.
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.
An adenocarcinoma of the thyroid gland, in which the cells are arranged in the form of follicles. (From Dorland, 27th ed)
A set of techniques used when variation in several variables has to be studied simultaneously. In statistics, multivariate analysis is interpreted as any analytic method that allows simultaneous study of two or more dependent variables.
The phenotypic manifestation of a gene or genes by the processes of GENETIC TRANSCRIPTION and GENETIC TRANSLATION.
Antibodies produced by a single clone of cells.
The uptake of naked or purified DNA by CELLS, usually meaning the process as it occurs in eukaryotic cells. It is analogous to bacterial transformation (TRANSFORMATION, BACTERIAL) and both are routinely employed in GENE TRANSFER TECHNIQUES.
An adenocarcinoma producing mucin in significant amounts. (From Dorland, 27th ed)
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
The loss of one allele at a specific locus, caused by a deletion mutation; or loss of a chromosome from a chromosome pair, resulting in abnormal HEMIZYGOSITY. It is detected when heterozygous markers for a locus appear monomorphic because one of the ALLELES was deleted.
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.
A CELL CYCLE and tumor growth marker which can be readily detected using IMMUNOCYTOCHEMISTRY methods. Ki-67 is a nuclear antigen present only in the nuclei of cycling cells.
The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability.
DNA sequences which are recognized (directly or indirectly) and bound by a DNA-dependent RNA polymerase during the initiation of transcription. Highly conserved sequences within the promoter include the Pribnow box in bacteria and the TATA BOX in eukaryotes.
The malignant stem cells of TERATOCARCINOMAS, which resemble pluripotent stem cells of the BLASTOCYST INNER CELL MASS. The EC cells can be grown in vitro, and experimentally induced to differentiate. They are used as a model system for studying early embryonic cell differentiation.
A class of fibrous proteins or scleroproteins that represents the principal constituent of EPIDERMIS; HAIR; NAILS; horny tissues, and the organic matrix of tooth ENAMEL. Two major conformational groups have been characterized, alpha-keratin, whose peptide backbone forms a coiled-coil alpha helical structure consisting of TYPE I KERATIN and a TYPE II KERATIN, and beta-keratin, whose backbone forms a zigzag or pleated sheet structure. alpha-Keratins have been classified into at least 20 subtypes. In addition multiple isoforms of subtypes have been found which may be due to GENE DUPLICATION.
Hybridization of a nucleic acid sample to a very large set of OLIGONUCLEOTIDE PROBES, which have been attached individually in columns and rows to a solid support, to determine a BASE SEQUENCE, or to detect variations in a gene sequence, GENE EXPRESSION, or for GENE MAPPING.
Genes that inhibit expression of the tumorigenic phenotype. They are normally involved in holding cellular growth in check. When tumor suppressor genes are inactivated or lost, a barrier to normal proliferation is removed and unregulated growth is possible.
Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms.
A malignant neoplasm occurring in young children, primarily in the liver, composed of tissue resembling embryonal or fetal hepatic epithelium, or mixed epithelial and mesenchymal tissues. (Stedman, 25th ed)
A thyroid neoplasm of mixed papillary and follicular arrangement. Its biological behavior and prognosis is the same as that of a papillary adenocarcinoma of the thyroid. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1271)
A multi-functional catenin that participates in CELL ADHESION and nuclear signaling. Beta catenin binds CADHERINS and helps link their cytoplasmic tails to the ACTIN in the CYTOSKELETON via ALPHA CATENIN. It also serves as a transcriptional co-activator and downstream component of WNT PROTEIN-mediated SIGNAL TRANSDUCTION PATHWAYS.
Small double-stranded, non-protein coding RNAs (21-31 nucleotides) involved in GENE SILENCING functions, especially RNA INTERFERENCE (RNAi). Endogenously, siRNAs are generated from dsRNAs (RNA, DOUBLE-STRANDED) by the same ribonuclease, Dicer, that generates miRNAs (MICRORNAS). The perfect match of the siRNAs' antisense strand to their target RNAs mediates RNAi by siRNA-guided RNA cleavage. siRNAs fall into different classes including trans-acting siRNA (tasiRNA), repeat-associated RNA (rasiRNA), small-scan RNA (scnRNA), and Piwi protein-interacting RNA (piRNA) and have different specific gene silencing functions.
Passages within the liver for the conveyance of bile. Includes right and left hepatic ducts even though these may join outside the liver to form the common hepatic duct.
A genus of FLAVIVIRIDAE causing parenterally-transmitted HEPATITIS C which is associated with transfusions and drug abuse. Hepatitis C virus is the type species.
In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test.
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.
The relationship between the dose of an administered drug and the response of the organism to the drug.
A type II keratin found associated with KERATIN-19 in ductal epithelia and gastrointestinal epithelia.
Calcium-dependent cell adhesion proteins. They are important in the formation of ADHERENS JUNCTIONS between cells. Cadherins are classified by their distinct immunological and tissue specificities, either by letters (E- for epithelial, N- for neural, and P- for placental cadherins) or by numbers (cadherin-12 or N-cadherin 2 for brain-cadherin). Cadherins promote cell adhesion via a homophilic mechanism as in the construction of tissues and of the whole animal body.
Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or malignant. Their classification and grading are based on the various cell types and the percent of undifferentiated cells.
The pathological process occurring in cells that are dying from irreparable injuries. It is caused by the progressive, uncontrolled action of degradative ENZYMES, leading to MITOCHONDRIAL SWELLING, nuclear flocculation, and cell lysis. It is distinct it from APOPTOSIS, which is a normal, regulated cellular process.
Furano-furano-benzopyrans that are produced by ASPERGILLUS from STERIGMATOCYSTIN. They are structurally related to COUMARINS and easily oxidized to an epoxide form to become ALKYLATING AGENTS. Members of the group include AFLATOXIN B1; aflatoxin B2, aflatoxin G1, aflatoxin G2; AFLATOXIN M1; and aflatoxin M2.
Blood tests that are used to evaluate how well a patient's liver is working and also to help diagnose liver conditions.
An adenocarcinoma characterized by the presence of varying combinations of clear and hobnail-shaped tumor cells. There are three predominant patterns described as tubulocystic, solid, and papillary. These tumors, usually located in the female reproductive organs, have been seen more frequently in young women since 1970 as a result of the association with intrauterine exposure to diethylstilbestrol. (From Holland et al., Cancer Medicine, 3d ed)
Regional infusion of drugs via an arterial catheter. Often a pump is used to impel the drug through the catheter. Used in therapy of cancer, upper gastrointestinal hemorrhage, infection, and peripheral vascular disease.
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
A country spanning from central Asia to the Pacific Ocean.
The movement of cells from one location to another. Distinguish from CYTOKINESIS which is the process of dividing the CYTOPLASM of a cell.
An enzyme that catalyzes the conversion of L-alanine and 2-oxoglutarate to pyruvate and L-glutamate. (From Enzyme Nomenclature, 1992) EC 2.6.1.2.
Proteins that are normally involved in holding cellular growth in check. Deficiencies or abnormalities in these proteins may lead to unregulated cell growth and tumor development.
Statistical models used in survival analysis that assert that the effect of the study factors on the hazard rate in the study population is multiplicative and does not change over time.
Tumors or cancer of the TONGUE.
The complex series of phenomena, occurring between the end of one CELL DIVISION and the end of the next, by which cellular material is duplicated and then divided between two daughter cells. The cell cycle includes INTERPHASE, which includes G0 PHASE; G1 PHASE; S PHASE; and G2 PHASE, and CELL DIVISION PHASE.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
FIBROSIS of the hepatic parenchyma due to chronic excess ALCOHOL DRINKING.
Tests to experimentally measure the tumor-producing/cancer cell-producing potency of an agent by administering the agent (e.g., benzanthracenes) and observing the quantity of tumors or the cell transformation developed over a given period of time. The carcinogenicity value is usually measured as milligrams of agent administered per tumor developed. Though this test differs from the DNA-repair and bacterial microsome MUTAGENICITY TESTS, researchers often attempt to correlate the finding of carcinogenicity values and mutagenicity values.
A malignant cystic or semicystic neoplasm. It often occurs in the ovary and usually bilaterally. The external surface is usually covered with papillary excrescences. Microscopically, the papillary patterns are predominantly epithelial overgrowths with differentiated and undifferentiated papillary serous cystadenocarcinoma cells. Psammoma bodies may be present. The tumor generally adheres to surrounding structures and produces ascites. (From Hughes, Obstetric-Gynecologic Terminology, 1972, p185)
A carcinoma discovered by Dr. Margaret R. Lewis of the Wistar Institute in 1951. This tumor originated spontaneously as a carcinoma of the lung of a C57BL mouse. The tumor does not appear to be grossly hemorrhagic and the majority of the tumor tissue is a semifirm homogeneous mass. (From Cancer Chemother Rep 2 1972 Nov;(3)1:325) It is also called 3LL and LLC and is used as a transplantable malignancy.
Substances used to allow enhanced visualization of tissues.
A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, and chemicals from the environment.
Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.
Small double-stranded, non-protein coding RNAs, 21-25 nucleotides in length generated from single-stranded microRNA gene transcripts by the same RIBONUCLEASE III, Dicer, that produces small interfering RNAs (RNA, SMALL INTERFERING). They become part of the RNA-INDUCED SILENCING COMPLEX and repress the translation (TRANSLATION, GENETIC) of target RNA by binding to homologous 3'UTR region as an imperfect match. The small temporal RNAs (stRNAs), let-7 and lin-4, from C. elegans, are the first 2 miRNAs discovered, and are from a class of miRNAs involved in developmental timing.
Injections introduced directly into localized lesions.
Diffusible gene products that act on homologous or heterologous molecules of viral or cellular DNA to regulate the expression of proteins.
Deoxyribonucleic acid that makes up the genetic material of viruses.
The number of new cases of a given disease during a given period in a specified population. It also is used for the rate at which new events occur in a defined population. It is differentiated from PREVALENCE, which refers to all cases, new or old, in the population at a given time.
An increase in the number of cells in a tissue or organ without tumor formation. It differs from HYPERTROPHY, which is an increase in bulk without an increase in the number of cells.
Tumors or cancer of the BRONCHI.
Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.
Methods which attempt to express in replicable terms the level of CELL DIFFERENTIATION in neoplasms as increasing ANAPLASIA correlates with the aggressiveness of the neoplasm.
Tumors or cancer of the SALIVARY GLANDS.
A method of hemostasis utilizing various agents such as Gelfoam, silastic, metal, glass, or plastic pellets, autologous clot, fat, and muscle as emboli. It has been used in the treatment of spinal cord and INTRACRANIAL ARTERIOVENOUS MALFORMATIONS, renal arteriovenous fistulas, gastrointestinal bleeding, epistaxis, hypersplenism, certain highly vascular tumors, traumatic rupture of blood vessels, and control of operative hemorrhage.
Nuclear antigen with a role in DNA synthesis, DNA repair, and cell cycle progression. PCNA is required for the coordinated synthesis of both leading and lagging strands at the replication fork during DNA replication. PCNA expression correlates with the proliferation activity of several malignant and non-malignant cell types.
Endogenous substances, usually proteins, which are effective in the initiation, stimulation, or termination of the genetic transcription process.

Intrahepatic recurrence after curative resection of hepatocellular carcinoma: long-term results of treatment and prognostic factors. (1/11254)

OBJECTIVE: This study aimed to evaluate the long-term results of treatment and prognostic factors in patients with intrahepatic recurrence after curative resection of hepatocellular carcinoma (HCC). SUMMARY BACKGROUND DATA: Recent studies have demonstrated the usefulness of re-resection, transarterial oily chemoembolization (TOCE), or percutaneous ethanol injection therapy (PEIT) in selected patients with intrahepatic recurrent HCC. The overall results of a treatment strategy combining these modalities have not been fully evaluated, and the prognostic factors determining survival in these patients remain to be clarified. METHODS: Two hundred and forty-four patients who underwent curative resection for HCC were followed for intrahepatic recurrence, which was treated aggressively with a strategy including different modalities. Survival results after recurrence and from initial hepatectomy were analyzed, and prognostic factors were determined by univariate and multivariate analysis using 27 clinicopathologic variables. RESULTS: One hundred and five patients (43%) with intrahepatic recurrence were treated with re-resection (11), TOCE (71), PEIT (6), systemic chemotherapy (8) or conservatively (9). The overall 1-year, 3-year, and 5-year survival rates from the time of recurrence were 65.5%, 34.9%, and 19.7%, respectively, and from the time of initial hepatectomy were 78.4%, 47.2%, and 30.9%, respectively. The re-resection group had the best survival, followed by the TOCE group. Multivariate analysis revealed Child's B or C grading, serum albumin < or = 40 g/l, multiple recurrent tumors, recurrence < or = 1 year after hepatectomy, and concurrent extrahepatic recurrence to be independent adverse prognostic factors. CONCLUSIONS: Aggressive treatment with a multimodality strategy could result in prolonged survival in patients with intrahepatic recurrence after curative resection for HCC. Prognosis was determined by the liver function status, interval to recurrence, number of recurrent tumors, any concurrent extrahepatic recurrence, and type of treatment.  (+info)

Identification of a cAMP response element within the glucose- 6-phosphatase hydrolytic subunit gene promoter which is involved in the transcriptional regulation by cAMP and glucocorticoids in H4IIE hepatoma cells. (2/11254)

The expression of a luciferase reporter gene under the control of the human glucose 6-phosphatase gene promoter was stimulated by both dexamethasone and dibutyryl cAMP in H4IIE hepatoma cells. A cis-active element located between nucleotides -161 and -152 in the glucose 6-phosphatase gene promoter was identified and found to be necessary for both basal reporter-gene expression and induction of expression by both dibutyryl cAMP and dexamethasone. Nucleotides -161 to -152 were functionally replaced by the consensus sequence for a cAMP response element. An antibody against the cAMP response element-binding protein caused a supershift in gel-electrophoretic-mobility-shift assays using an oligonucleotide probe representing the glucose 6-phosphatase gene promoter from nucleotides -161 to -152. These results strongly indicate that in H4IIE cells the glucose 6-phosphatase gene-promoter sequence from -161 to -152 is a cAMP response element which is important for the regulation of transcription of the glucose 6-phosphatase gene by both cAMP and glucocorticoids.  (+info)

Tumour ablation and hepatic decompensation rates in multi-agent chemoembolization of hepatocellular carcinoma. (3/11254)

Thirty-seven cirrhotic patients with 62 hepatocellular carcinoma (HCC) foci--most Child-Pugh class B or C and/or with large, inoperable tumours--underwent 148 sessions of transcatheter arterial chemoembolization (TACE) using lipiodol, doxorubicin and cisplatin. Treatment efficacy was assessed by serial hepatic arteriography in 34/37 (91.9%) patients and abdominal CT scanning in 3/37 (8.1%) patients. Child-Pugh status was determined prior to each treatment session. Varying degrees of control of tumour neovascularity occurred for a median 390 days (range 90 to > 1680 days) in 33/34 (97.1%) patients in whom progress hepatic arteriography was performed. Ablation of tumour neovascularity occurred in 6/6 (100%), 4/12 (33.3%) and 6/16 (37.5%) patients with HCC diameters < 4 cm, 4-7 cm and > 8 cm, respectively (p < 0.02). Significantly more sessions were required for ablation of larger tumours (p < 0.05). Recurrent HCC was detected in 50% of patients after a median 240 days (range 60-1120 days). Deterioration in Child-Pugh status followed a session of TACE on 19/148 (12.8%) occasions but resulted in unscheduled hospitalization on only 4/148 (2.7%) occasions, the highest incidence (8.3%) in Child-Pugh C patients. Actuarial survival was 27/36 (75.0%) at 6 months, 17/34 (50.0%) at 12 months, 14/34 (41.2%) at 18 months, 9/31 (29.0%) at 24 months and 4/27 (14.8%) at 36 months. Multi-agent TACE with lipiodol, doxorubicin and cisplatin provides a useful anti-tumour effect, even in cirrhotic patients with large HCCs. The incidence of clinically significant deterioration in hepatic function due to ischaemia of non-tumorous liver is acceptably low, even in Child-Pugh C patients.  (+info)

Clinical significance of circulating anti-p53 antibodies in European patients with hepatocellular carcinoma. (4/11254)

p53 alterations are considered to be predictive of poor prognosis in hepatocellular carcinoma (HCC) and may induce a humoral response. Anti-p53 serum antibodies were assessed by enzyme-linked immunosorbent assay (ELISA) using purified recombinant human p53 on 130 European HCC patients before treatment and during the clinical course of the disease. p53 immunohistochemistry was performed on tumours from the 52 patients who underwent surgery, and DNA sequencing analysis was initiated when circulating anti-p53 antibodies were detected. Nine (7%) HCC patients had anti-p53 serum antibodies before treatment. During a mean period of 30 months of follow-up, all the negative patients remained negative, even when recurrence was observed. Of the nine positive patients, eight were still positive 12-30 months after surgery. The presence of anti-p53 serum antibodies was correlated neither with mutation of the p53 gene nor the serum alpha-fetoprotein levels and clinicopathological characteristics of the tumours. However, a greater incidence of vascular invasion and accumulation of p53 protein were observed in the tumours of these patients (P<0.03 and P<0.01 respectively) as well as a better survival rate without recurrence (P = 0.05). In conclusion, as was recently shown in pancreatic cancer, anti-p53 serum antibodies may constitute a marker of relative 'good prognosis' in a subgroup of patients exhibiting one or several markers traditionally thought to be of bad prognosis.  (+info)

Mutant p53 can provoke apoptosis in p53-deficient Hep3B cells with delayed kinetics relative to wild-type p53. (5/11254)

Wild-type (wt) p53 frequently induces apoptosis when expressed in tumor cells whereas mutant p53 acts as an oncoprotein and consequently, stimulates cell proliferation. We report here exceptions to that rule. p53 conformational mutant 175H and DNA contact mutant 273H provoke apoptosis in human p53-deficient Hep3B hepatoma cells with delayed kinetics relative to wt p53. Similarly, c-Myc strongly stimulates apoptosis in these cells. In contrast, viral oncoproteins E1A and E7, and the cellular oncoprotein MDM-2, fail to elicit cytocidal responses. Efficient apoptotic cell death by mutant p53 requires oligomerization as 175H and 273H with deletions between amino acid residues 326 and 347 of the oligomerization domain are nontoxic. Apoptosis by mutant or wt p53 was significantly inhibited by the serine protease inhibitor AEBSF but not by the inactive analog AEBSA. Together, these results suggest that a wt p53-independent control mechanism is operational in Hep3B cells that eliminates cells upon sensing illegitimate proliferation signals originating from certain oncoproteins, including mutant p53 and Myc. We suggest that some tumor cell types lack p53 altogether because they tolerate neither wild-type nor mutant forms of the protein.  (+info)

Enhanced mitochondrial biogenesis is associated with increased expression of the mitochondrial ATP-dependent Lon protease. (6/11254)

Rats bearing the Zajdela hepatoma tumor and T3-treated hypothyroid rats were used to study the role of protein degradation in the process of mitochondrial biogenesis. It was shown that the activity, protein and mRNA levels of the ATP-dependent Lon protease increased in rapidly growing Zajdela hepatoma cells. The increase in the rate of mitochondrial biogenesis by thyroid hormone was similarly accompanied by enhanced expression of the Lon protease. The results imply that mitochondrial biogenesis in mammalian cells is, at least partially, regulated by the matrix Lon protease.  (+info)

Homologous regulation of the alpha2C-adrenoceptor subtype in human hepatocarcinoma, HepG2. (7/11254)

1. Previous studies of the regulation of the alpha2C-adrenoceptor in OK and in transfected cells have led to discrepant conclusions. In the present work, we examined the homologous regulation of the human alpha2C-adrenoceptor in the hepatocarcinoma cell-line, HepG2; a model which expresses this subtype spontaneously. 2. Short-period treatment of the cells with UK14304 provoked neither a diminution of the potency of the alpha2-agonist to inhibit forskolin-induced cyclic AMP-accumulation nor a change in the degree of receptor coupling to G-proteins. 3. Long-period exposure to UK14304 resulted in a large reduction of [3H]MK912 binding sites (55% decrease). The action of UK14304 was dose-dependent (EC50 = 190 +/- 45 nM), rapid (t1/2 = 4.2 h) and reversible. Receptor down-regulation was also observed with clonidine or (-)adrenaline (38 and 36% decrease, respectively) and was blocked by the addition of alpha2-antagonists. 4. Conversely to that observed with alpha2-agonists, treatment of the cells with RX821002 or yohimbine alone, but not with phentolamine, promoted a significant increase of the receptor expression. 5. The observed alterations of receptor density are not the reflection of changes at the alpha2C4 mRNA level. Estimation of the receptor protein turnover and measurement of its half-life demonstrated that down-regulation by alpha2-agonists and up-regulation by alpha2-antagonists, with inverse-agonist efficacy, are respectively the consequence of increased and decreased rate of receptor degradation. 6. In conclusion, our data show that alpha2C-adrenoceptor does not undergo desensitization but is down-regulated in HepG2. The lack of desensitization agrees with previous results obtained in cells transfected with the alpha2C4 gene, but not with observations made in OK cells. Inversely, down-regulation fits with results obtained in OK but not in transfected cells. The reasons for these discrepancies are discussed. Our results also demonstrated that certain alpha2-antagonists behave as inverse agonist on the HepG2 model and thus provide for the first time evidence of inverse efficacy of antagonists on a cellular model expressing physiological level of a wild-type alpha2-adrenoceptor.  (+info)

Variation of liver-type fatty acid binding protein content in the human hepatoma cell line HepG2 by peroxisome proliferators and antisense RNA affects the rate of fatty acid uptake. (8/11254)

The liver-type fatty acid binding protein (L-FABP), a member of a family of mostly cytosolic 14-15 kDa proteins known to bind fatty acids in vitro and in vivo, is discussed to play a role in fatty acid uptake. Cells of the hepatoma HepG2 cell line endogenously express this protein to approximately 0.2% of cytosolic proteins and served as a model to study the effect of L-FABP on fatty acid uptake, by manipulating L-FABP expression in two approaches. First, L-FABP content was more than doubled upon treating the cells with the potent peroxisome proliferators bezafibrate and Wy14,643 and incubation of these cells with [1-14C]oleic acid led to an increase in fatty acid uptake rate from 0.55 to 0.74 and 0.98 nmol/min per mg protein, respectively. In the second approach L-FABP expression was reduced by stable transfection with antisense L-FABP mRNA yielding seven clones with L-FABP contents ranging from 0.03% to 0.14% of cytosolic proteins. This reduction to one sixth of normal L-FABP content reduced the rate of [1-14C]oleic acid uptake from 0.55 to 0. 19 nmol/min per mg protein, i.e., by 66%. The analysis of peroxisome proliferator-treated cells and L-FABP mRNA antisense clones revealed a direct correlation between L-FABP content and fatty acid uptake.  (+info)

Fibrolamellar hepatocellular carcinoma (FLC) is a rare subtype of primary liver cancer. Fibrolamellar hepatocellular carcinoma was first described Edmondson in 1956.[1][2] Fibrolamellar hepatocellular carcinoma is most commonly seen in children and young adults. The pathogenesis of fibrolamellar hepatocellular carcinoma is characterized by the lack of cirrhosis. Common causes of fibrolamellar hepatocellular carcinoma, include: active hepatic inflammation, hepatitis B or C viral infection, alcohol-related liver disease, nonalcoholic fatty liver disease, and dietary aflatoxin B1. The majority of patients with fibrolamellar hepatocellular carcinoma remain asymptomatic for years. Early clinical features include abdominal pain, weight loss, and malaise. If left untreated, the majority of patients with fibrolamellar hepatocellular carcinoma may progress to develop metastasis to abdominal lymph nodes, peritoneum, and lung. Common complications of fibrolamellar hepatocellular carcinoma include: hepatic ...
Headline: Bitcoin & Blockchain Searches Exceed Trump! Blockchain Stocks Are Next!. Metastatic Hepatocellular Carcinoma (HCC) market report covers research informatics related to Metastatic Hepatocellular Carcinoma (HCC) clinical trials, such as a listing of industry and sponsored clinical trials as well as new drug therapies.. Designed to be a resource both for patients interested in participating in Metastatic Hepatocellular Carcinoma (HCC) clinical trials and for research professionals.. The report, Metastatic Hepatocellular Carcinoma (HCC) Global Clinical Trials Review, H2, 2016″ provides an overview of Metastatic Hepatocellular Carcinoma (HCC) clinical trials scenario. This report provides top line data relating to the clinical trials on Metastatic Hepatocellular Carcinoma (HCC). Report includes an overview of trial numbers and their average enrolment in top countries conducted across the globe. The report also offers coverage of disease clinical trials by region, country (G7 & E7), ...
TY - JOUR. T1 - First-time use of bevacizumab for aggressive, metastatic hepatocellular carcinoma in an HIV/hepatitis B virus coinfected patient. T2 - A case report. AU - Baraboutis, Ioannis G.. AU - Papastamopoulos, Vassilios. AU - Charitsis, Georgios. AU - Lekakis, Lazaros J.. AU - Vaslamatzis, Michael M.. AU - Skoutelis, Athanasios T.. PY - 2008/5/1. Y1 - 2008/5/1. N2 - We present a case of an HIV-1 infected patient with history of chronic hepatitis B and chronic alcohol use without cirrhosis, who presented with aggressive hepatocellular carcinoma with multiple metastases. Systemic chemotherapy combined with use of bevacizumab (anti-vascular endothelium growth factor monoclonal antibody) was without effect and the patient succumbed to his disease within few weeks. To our knowledge, this is the first report in the English literature of bevacizumab use for metastatic hepatocellular carcinoma in HIV-infected patients.. AB - We present a case of an HIV-1 infected patient with history of chronic ...
Gehring, A.J., Ho, Z.Z., Tan, A.T., Bertoletti, A., Aung, M.O., Lim, S.G., Lee, K.H., Tan, K.C., Lim, S.G. (2009). Profile of Tumor Antigen-Specific CD8 T Cells in Patients With Hepatitis B Virus-Related Hepatocellular Carcinoma. Gastroenterology 137 (2) : 682-690. [email protected] Repository. https://doi.org/10.1053/j.gastro.2009.04. ...
BACKGROUND AND AIM: Patients with persistently active hepatitis B virus (HBV) replication are at high risk for progression to liver cirrhosis and hepatocellular carcinoma (HCC). The influence of the viral load of HBV on intrahepatic recurrence after local ablation therapy in patients with HBV-related HCC has not been elucidated. We aimed to evaluate predictors of intrahepatic recurrence and clarify the correlation between viral load and intrahepatic recurrence after percutaneous ablation.. METHODS: Patients with HBV-related, solitary HCC undergoing radiofrequency ablation (RFA) or percutaneous ethanol injection (PEI), between October 2004 and December 2008 were prospectively enrolled. Statistical analyses were performed using the Kaplan-Meier method and Cox regression model to identify risk factors for intrahepatic recurrence.. RESULTS: A total of 145 patients (male, 81.4%; mean age, 55.3 years) were included. Ninety patients (62.1%) had serum HBV DNA ≥2000 IU/mL. The median follow-up duration ...
TY - JOUR. T1 - Effects of MACC1 polymorphisms on hepatocellular carcinoma development and clinical characteristics. AU - Lin, Chien Hua. AU - Hsieh, Ming Ju. AU - Lee, Hsiang Lin. AU - Yang, Shun Fa. AU - Su, Shih Chi. AU - Lee, Wei Jiunn. AU - Chou, Ying Erh. PY - 2020/1/1. Y1 - 2020/1/1. N2 - Hepatocellular carcinoma (HCC) is a major malignancy of cancer-related mortality worldwide. Metastasis-associated in colon cancer-1 (MACC1) was suggested as a marker for vascular invasive HCC. This study investigated the MACC1 single-nucleotide polymorphisms (SNPs) to evaluate HCC susceptibility and clinicopathological characteristics. In this study, real-time polymerase chain reaction was applied to analyze five SNPs of MACC1 rs1990172, rs975263, rs3095007, rs4721888, and rs3735615 in 378 patients with HCC and 1199 cancer-free controls. The results showed that in 151 HCC patients among smokers who carried MACC1 rs1990172 CA + AA variants had a lower risk of developing a large tumor (odds ratio [OR] = ...
On May 29, 2020, the FDA approved the immunotherapy atezolizumab (Tecentriq; Genentech), a PD-L1 inhibitor, in combination with bevacizumab (Avastin; Genentech), a vascular endothelial growth factor inhibitor, for the treatment of patients with unresectable or metastatic hepatocellular carcinoma (HCC) who have not received systemic therapy. This is the first immunotherapy regimen approved by the FDA for this type of HCC.
Fibrolamellar hepatocellular carcinoma (FHCC) is a rare form of hepatocellular carcinoma (HCC) that typically affects young adults and is characterized, under the microscope, by laminated fibrous layers interspersed between the tumour cells. Approximately 200 new cases are diagnosed worldwide each year. A recent study showed the presence of the DNAJB1-PRKACA chimeric transcript (resulting from a 400kb somatic deletion on chromosome 19) in 100% of the FHCCs examined (15/15) This gene fusion has been confirmed in a second study. The histopathology of FHCC is characterized by laminated fibrous layers, interspersed between the tumor cells. Cytologically, the tumor cells have a low nuclear to cytoplasmic ratio with abundant eosinophilic cytoplasm. Tumors are non-encapsulated, but well circumscribed, when compared to conventional HCC (which typically has an invasive border). Due to lack of symptoms, until the tumor is sizable, this form of cancer is often advanced when diagnosed. Symptoms include ...
Sigma-Aldrich offers abstracts and full-text articles by [Seung In Seo, Hyoung Su Kim, Won Jin Kim, Woon Geon Shin, Doo Jin Kim, Kyung Ho Kim, Myoung Kuk Jang, Jin Heon Lee, Joo Seop Kim, Hak Yang Kim, Dong Joon Kim, Myung Seok Lee, Choong Kee Park].
Hepatoma Research is an open access journal and focuses on all topics related to hepatoma. The following articles are especially welcome: pathogenesis, clinical examination and early diagnosis of hepatoma, complications of hepatoma, and their preventions and treatments, etc.
It has been estimated that 70% to 90% of patients with hepatocellular carcinomas have an established background of chronic liver disease or cirrhosis, the major causes of which are HBV or HCV infection (26, 27). More than 50% (340,000 cases) of all hepatocellular carcinomas worldwide are associated with HBV infection and near 30% (195,000 cases) are HCV infection-related (28, 29). Once cirrhosis is established, the annual risk of developing hepatocellular carcinoma is estimated to be as high as 3% to 4% (30). Screening for hepatocellular carcinoma using serum AFP or combined with ultrasonography in these high-risk populations is still the essential way for detection and diagnosis of hepatocellular carcinomas at an earlier stage, when curative therapies are likely to be more successful (31, 32).. On the basis of the specific screening requirements for hepatocellular carcinomas in the context of chronic liver disease and cirrhosis and the general criteria for an adequate screening test to detect ...
Fibrolamellar hepatocellular carcinoma (FL-HCC) is a rare liver tumor affecting adolescents and young adults with no history of primary liver disease or cirrhosis. We identified a chimeric transcript that is expressed in FL-HCC but not in adjacent normal liver and that arises as the result of a ∼400-kilobase deletion on chromosome 19. The chimeric RNA is predicted to code for a protein containing the amino-terminal domain of DNAJB1, a homolog of the molecular chaperone DNAJ, fused in frame with PRKACA, the catalytic domain of protein kinase A. Immunoprecipitation and Western blot analyses confirmed that the chimeric protein is expressed in tumor tissue, and a cell culture assay indicated that it retains kinase activity. Evidence supporting the presence of the DNAJB1-PRKACA chimeric transcript in 100% of the FL-HCCs examined (15/15) suggests that this genetic alteration contributes to tumor pathogenesis ...
To the editor: We are writing in response to the letter (1) on fibrolamellar hepatocellular carcinoma, in which Ruffin points out that the cases of this tumor reported since 1941 have all originated in the United States. We report two cases of this tumor diagnosed in patients treated at our hospital.. A 25-year-old man was hospitalized for epigastric discomfort; anorexia was present for 5 months. Physical examination showed a liver edge 12 cm below the right costal margin. The erythrocyte sedimentation rate was 135 mm/h; alkaline phosphatase, 100 U/L (normal, ≤ 40 U/L); and gamma-glutamyltransferase, 89 IU/L (normal, ≤ 30 ...
MicroRNAs (miRNAs) are non-coding small RNAs that can function as gene regulators and are involved in tumorigenesis. We review the commonly dysregulated miRNAs in liver tumor tissues and plasma/serum of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) patients. The frequently reported up-regulated miRNAs in liver tumor tissues include miR-18a, miR-21, miR-221, miR-222, and miR-224, whereas down-regulated miRNAs include miR-26a, miR-101, miR-122, miR-125b, miR-145, miR-199a, miR-199b, miR-200a, and miR-223. For a subset of these miRNAs (up-regulated miR-222 and miR-224, down-regulated miR-26a and miR-125b), the pattern of dysregulated circulating miRNAs in plasma/serum is mirrored in tumor tissue based on multiple independent studies. Dysregulated miRNAs target oncogenes or tumor suppressor genes involved in hepatocarcinogenesis. Normalization of dysregulated miRNAs by up- or down-regulation has been shown to inhibit HCC cell proliferation or sensitize liver cancer cells to chemotherapeutic
Dynamic monitoring of serum alpha-fetoprotein and its correlation with early hepatocellular carcinoma in patients with chronic hepatitis B, Qing-Feng Chen, Xiao-Min Luo, Mei-Ping Z
AIM: To investigate the antitumor effects of cytosine deaminase (CD) gene in combination with prodrug flucytosine (Flu, 5-fluorocytosine) on human hepatocellular carcinoma. METHODS: CD gene was transduced into human hepatocellular carcinoma cell line
TY - JOUR. T1 - Altered findings of hepatic arteriography after radiofrequency ablation of hepatocellular carcinoma. T2 - Comparison of pre-ablation and post-ablation angiograms. AU - Kim, Byung Moon. AU - Cho, Jae Hyun. AU - Won, Je Hwan. AU - Lee, Do Yun. AU - Lee, Jong Tae. AU - Kim, Hyun Cheol. AU - Park, Sung Il. PY - 2007/6/1. Y1 - 2007/6/1. N2 - Objective: To evaluate the altered findings of hepatic arteriography after radiofrequency (RF) ablation of hepatocellular carcinoma which can potentially influence subsequent transcatheter arterial chemoembolization. Materials and methods: Hepatic arteriograms of 26 index hepatocellular carcinomas in 24 patients treated only by RF ablation (M:F = 22:2, mean age 55 years), in which hepatic arteriography was performed before and after RF ablation, were retrospectively compared for the altered findings. Results: The altered findings of hepatic arteriography after RF ablation of the hepatocellular carcinoma were arterio-portal shunt (n = 3), ...
TY - JOUR. T1 - Teroxirone suppresses growth and motility of human hepatocellular carcinoma cells. AU - Kim, Seung Hun. AU - Wang, Wen Hsing. AU - Wang, Jing Ping. AU - Hsieh, Chang Heng. AU - Fang, Kang. PY - 2018/3. Y1 - 2018/3. N2 - Aims: The prevalent human hepatocellular carcinoma (HCC) is a leading cause of global cancer-related mortality. The small molecular weight triepoxide derivative, 1,3,5-triazine-2,4,6(1H,3H,5H)-tri-one-1,3,5-tri-(oxiranylmethyl) (teroxirone), has been proved effective against the proliferation of lung cancer cells. The purpose is to further examine if teroxirone regulate growth and metastatic potential of HCC cells with aims at disclosing more of the reaction mechanisms. Main methods: Measurements of cell viability and flow cytometry were conducted to test sensitivities of teroxirone against HCC cells. The signaling pathway leading to apoptotic death was unraveled by Western blotting analysis. The metastatic progression was evaluated by cell-based phenotype assay ...
TY - JOUR. T1 - Ferucarbotran-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma. AU - Kim, Seong Hyun. AU - Choi, Dongil. AU - Kim, Seung Hoon. AU - Lim, Jae Hoon. AU - Lee, Won Jae. AU - Kim, Min Ju. AU - Lim, Hyo K.. AU - Lee, Soon Jin. PY - 2005/1/1. Y1 - 2005/1/1. N2 - OBJECTIVE. We compared ferucarbotran-enhanced MRI with triple-phase MDCT for the preoperative detection of hepatocellular carcinoma. SUBJECTS AND METHODS. Seventy-three consecutive patients with 121 hepatocellular carcinomas underwent ferucarbotran-enhanced MRI, including a dynamic study, and triple-phase MDCT before hepatic resection. The diagnosis of hepatocellular carcinoma was confirmed in all patients by means of pathologic examination after surgical resection. Three experienced radiologists independently reviewed the MR and CT images on a segment-by-segment basis. The accuracy of these techniques for the detection of hepatocellular carcinoma was assessed by conducting a ...
Many chemotherapeutic agents have been successfully used to treat hepatocellular carcinoma (HCC);however, the development of chemoresistance in liver cancer cells usually results in a relapse and worseningof prognosis. It has been demonstrated that DNA methylation and histone modification play crucial roles inchemotherapy resistance. Currently, extensive research has shown that there is another potential mechanismof gene expression control, which is mediated through the function of short noncoding RNAs, especially formicroRNAs (miRNAs), but little is known about their roles in cancer cell drug resistance. In present study, bytaking advantage of miRNA effects on the resistance of human hepatocellular carcinoma cells line to cisplatin, ithas been demonstrated that miR-340 were significantly downregulated whereas Nrf2 was upregulated in HepG2/CDDP (cisplatin) cells, compared with parental HepG2 cells. Bioinformatics analysis and luciferase assays ofNrf2-3-untranslated region-based reporter constructor
Description of disease Hepatocellular carcinoma. Treatment Hepatocellular carcinoma. Symptoms and causes Hepatocellular carcinoma Prophylaxis Hepatocellular carcinoma
TY - JOUR. T1 - Lipocalin-2 Induces Apoptosis in Human Hepatocellular Carcinoma Cells Through Activation of Mitochondria Pathways. AU - Chien, Ming Hsien. AU - Ying, Tsung Ho. AU - Yang, Shun Fa. AU - Yu, Ji Kuen. AU - Hsu, Chih Wei. AU - Hsieh, Shu Ching. AU - Hsieh, Yi Hsien. PY - 2012. Y1 - 2012. N2 - Lipocalin 2 (LCN2) is a secreted, iron-binding glycoprotein that is abnormally expressed in some malignant human cancers. However, the roles of LCN2 in hepatocellular carcinoma (HCC) cells are unknown. In this study, we suggested the LCN2 and LCN2R were weak detected in the HCC cell lines, LCN2 and LCN2R were found to be down-regulated in tumor tissues in 16 HCC patients. MTT, DAPI, TUNEL, and flow cytometry analyses revealed that LCN2 overexpression dramatically inhibited cell viability, induced apoptosis features of cell-cycle arrest in sub-G1 phase, in DNA fragmentation, and in condensation of chromatin in Huh-7 and SK-Hep-1 cells. Western blots were used to detect the activation of caspase, ...
Hepatocellular carcinoma (HCC) is a serious consequence of persistent hepatitis C virus (HCV) infection and represents one of the most aggressive neoplasms globally. The implication of microRNA-301...
HCC is the third most common cancer worldwide, causing about 700,000 deaths annually.2 It is associated with cirrhosis, hepatitis B and C virus, primary biliary and sclerosing cholangitis, aflatoxins, and autoimmune hepatitis.2,3 Extrahepatic metastatic HCC, as observed in this case, occur in 30-50% of HCC patients; the most common sites are lungs, bones, adrenal glands, and lymph nodes.4 Rare and unusual metastatic sites have been described in the literature, including the chest wall presenting as a breast mass and metastasis to the nasal septum.5,6 Indeed, extrahepatic metastases to the humeral shoulder, chest wall, and bony lesions are exceedingly rare, as only a handful of cases have been reported.3,7 Traditionally, a few systems have been widely employed for HCC staging (e.g. Okuda, tumor/node/metastasis), however, newer classification systems that take into account prognostication and treatment regimens are increasingly being utilized.8 The Cancer of the Liver Italian Program (CLIP) and ...
TY - JOUR. T1 - Systemic cytotoxic chemotherapy of patients with advanced hepatocellular carcinoma in the era of sorafenib nonavailability. AU - Yoon, Eileen L.. AU - Yeon, Jong Eun. AU - Lee, Hyun Jung. AU - Suh, Sang Jun. AU - Lee, Sun Jae. AU - Kang, Seong Hee. AU - Kang, Keunhee. AU - Yoo, Yang Jae. AU - Kim, Ji Hoon. AU - Yim, Hyung Joon. AU - Byun, Kwan Soo. PY - 2014/3/1. Y1 - 2014/3/1. N2 - GOALS:: The goal of the study was to compare the efficacy and safety of sorafenib with those of systemic cytotoxic chemotherapy. BACKGROUND:: Sorafenib treatment has shown to improve the survival in patients with advanced hepatocellular carcinoma (HCC) when compared with placebo. However, whether sorafenib controls advanced-stage HCC better than systemic cytotoxic chemotherapy has not been elucidated. STUDY:: We retrospectively reviewed the medical records of 220 patients with measurable advanced HCC who had not received systemic treatment previously between January 2007 and April 2012. Among these ...
TY - JOUR. T1 - Recurrent hepatocellular carcinoma after liver transplant. T2 - Identifying the high-risk patient. AU - Nissen, Nicholas N.. AU - Menon, Vijay. AU - Bresee, Catherine. AU - Tran, Tram T.. AU - Annamalai, Alagappan. AU - Poordad, Fred. AU - Fair, Jeffrey H.. AU - Klein, Andrew S.. AU - Boland, Brendan. AU - Colquhoun, Steven D. PY - 2011/1/1. Y1 - 2011/1/1. N2 - Background: Recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT) is rarely curable. However, in view of the advent of new treatments, it is critical that patients at high risk for recurrence are identified. Methods: Patients undergoing LT for HCC at a single centre between 2002 and 2010 were reviewed and data on clinical parameters and explant pathology were analysed to determine factors associated with HCC recurrence. All necrotic and viable tumour nodules were included in explant staging. All patients underwent LT according to the United Network for Organ Sharing (UNOS) Model for End-stage Liver ...
TY - JOUR. T1 - Combination chemotherapy with continuous 5-fluorouracil and low-dose cisplatin infusion for advanced hepatocellular carcinoma. AU - Tanioka, Hiroaki. AU - Tsuji, Akihito. AU - Morita, Sojiro. AU - Horimi, Tadashi. AU - Takamatsu, Masahiro. AU - Shirasaka, Tetsuhiko. AU - Mizushima, Takaaki. AU - Ochi, Koji. AU - Kiura, Katsuyuki. AU - Tanimoto, Mitsune. PY - 2003/3/1. Y1 - 2003/3/1. N2 - Background: In this study we evaluated the efficacy and toxicities of combination chemotherapy consisting of continuous 5-fluorouracil (5-FU) infusion and low-dose cisplatin infusion (low-dose FP therapy) in the treatment of advanced hepatocellular carcinoma (HCC). Materials and Methods: Thirty-eight patients with advanced HCC in whom local treatment was not indicated were enrolled. The low-dose FP therapy consisted of 5-FU (170mg/m2/day on days 1 to 7/week, continuous infusion) and cisplatin (3mg/m2/day in 100ml normal saline, infusion more than 30 minutes, on days 1 to 5/week). The patients ...
Gentaur molecular products has all kinds of products like :search , US Biomax \ Hepatocellular carcinoma tissue array, 63 cases_63 cores, replaced by LV809 \ BS03014 for more molecular products just contact us
Sorafenib improves overall survival and progression free survival in advanced hepatocellular carcinoma. Wide interindividual pharmacokinetic variability was observed. Data from early phase trials in solid tumours showed trough sorafenib levels were associated with incidence of skin rash and hypertension. Rash, hypertension and higher trough levels were moderately predictive of progression free survival.The trough level of sorafenib may be predictive of survival and response in patients treated with sorafenib for advanced hepatocellular carcinoma ...
Background To compare the RapidArc plan for primary hepatocellular carcinoma (HCC) with 3-D conformal radiotherapy (3DCRT) and intensity-modulated radiotherapy (IMRT) plans using dosimetric analysis.
We describe a case of acute liver failure in a patient with advanced hepatocellular carcinoma related to nonalcoholic steatohepatitis during sorafenib treatment. A 74-year-old man with diabetes mellitus and hypertension was diagnosed with hepatocellular carcinoma associated with fatty liver. Three weeks after sorafenib therapy, at Eastern Cooperative Oncology Group performance status 3, he developed jaundice, general weakness, flapping tremor, nausea, and anorexia. Sorafenib was stopped: laboratory tests showed a relevant elevation of transaminases suggesting diagnosis of acute hepatitis. During hospital admission, the patient died of liver failure. Sorafenib is the first successful target therapy effective for advanced hepatocellular carcinoma. The most common adverse events are fatigue, hand-foot skin reaction, skin rash/desquamation, diarrhea, and hypertension, whereas liver dysfunction is uncommon. To our knowledge, this is the first patient reported in the literature with hepatocellular ...
TY - JOUR. T1 - Surgical Resection vs. Ablative Therapies Through a Laparoscopic Approach for Hepatocellular Carcinoma: a Comparative Study. AU - Santambrogio, Roberto. AU - Santambrogio, Roberto. AU - Barabino, Matteo. AU - Bruno, Savino. AU - Mariani, Nicolò. AU - Maroni, Nirvana. AU - Bertolini, Emanuela. AU - Franceschelli, Giuseppe. AU - Opocher, Enrico. PY - 2017/12/12. Y1 - 2017/12/12. N2 - © 2017 The Society for Surgery of the Alimentary Tract Background: When compatible with the liver functional reserve, laparoscopic hepatic resection remains the treatment of choice for hepatocellular carcinoma while laparoscopic ablation therapies appear as a promising less invasive alternative. The aim of the study is to compare two homogeneous groups of patients submitted to either hepatic resection or thermoablation for the treatment of single hepatocellular carcinoma (≤ 3 cm). Methods: We enrolled 264 cirrhotic patients out of 905 cases consecutively evaluated for hepatocellular carcinoma. We ...
To evaluate the clinical efficacy of interferon-α in hepatocellular carcinoma, 71 adult Chinese patients with histologically proven inoperable hepatocellular carcinoma were randomized to receive recombinant interferon- α(2a) (50 x 106 IU/m2) intramuscularly three times a week (n = 35) or no antitumor therapy (n = 36). The survival of interferon-α-treated patients was significantly better than that of patients who received no antitumor therapy (p = 0.0471); median lengths of survival were 14.5 and 7.5 wk, respectively. Objective tumor regression greater than 50% was observed in 31.4% (11 of 35) of patients receiving interferon-α. Interferon-α induced tumor regression greater than 50% in 11 (31.4%) patients. Compared with the group receiving no antitumor therapy, the interferon-α therapy group had more tumor regression (p < 0.0001) and less tumor progression (p = 0.001). This high-dose interferon-α therapy was relatively well tolerated; only 34.3% of patients required reduction of dosage by ...
Objective To investigate the associated complication of small Hepatocellular carcinoma near the top of diaphragm with the treatment of radiofrequency ablation (RFA) and the safety of the CT-guided RFA. Methods 43 cases with 67 lesions received the intentional procedure of RFA. Results All lesions completely necrosis rates was 92.5%(62/67), the lesions (diameter≤3.0 cm) was 94.2%(49/52) and the lesions (diameter3.1 cm) was 86.7%(13/15). There was no treatment-related mortality in the studied group. The major complications included ache (26 cases), dyspnoea (7 cases), pleural effusion (6 case), pneumothorax (3 case), tsubcapsular hemorrhag of liver (3 case), hiccup (6 cases). Conclusion RFA is a safe minimal invasive method in the treatment of small hepatocellular carcinoma near the top of diaphragm.
TY - JOUR. T1 - An overview of loco-regional treatments in patients and mouse models for hepatocellular carcinoma. AU - Bimonte, Sabrina. AU - Barbieri, Antonio. AU - Palaia, Raffaele. AU - Leongito, Maddalena. AU - Albino, Vittorio. AU - Piccirillo, Mauro. AU - Arra, Claudio. AU - Izzo, Francesco. PY - 2015/3/9. Y1 - 2015/3/9. N2 - Hepatocellular carcinoma is a highly aggressive malignancy and is the third leading cause of cancer-related deaths worldwide. Although surgery is currently considered the most effective curative treatment for this type of cancer, it is note that most of patients have a poor prognosis due to chemioresistence and tumor recurrence. Loco-regional therapies, including radiofrequency ablation, surgical resection and transcatheter arterial chemoembolization play a major role in the clinical management of hepatocellular carcinoma. In order to improve the treatment outcome of patients diagnosed with this disease, several in vivo studies by using different techniques on cancer ...
1. Patel M, Shariff M I, Ladep N G. et al. Hepatocellular carcinoma: diagnostics and screening. J Eval Clin Pract. 2012;18:335-42 2. Padhya K T, Marrero J A, Singal A G. Recent advances in the treatment of hepatocellular carcinoma. Curr Opin Gastroenterol. 2013;29:285-92 3. Schoenleber S J, Kurtz D M, Talwalkar J A, Roberts L R, Gores G J. Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis. Br J Cancer. 2009;100:1385-92 4. Miura S, Mitsuhashi N, Shimizu H. et al. Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma. BMC Cancer. 2012;12:56 5. Lassalle P, Molet S, Janin A. et al. ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines. J Biol Chem. 1996;271:20458-64 6. Bechard D, Meignin V, Scherpereel A. et al. Characterization of the secreted form of endothelial-cell-specific molecule 1 by specific monoclonal ...
Background and aims. Information on the impact of therapeutic strategies of hepatocellular carcinoma is still incomplete due to the lack of surveys involving primary-care centres. Patients and methods. The Gruppo Epatologico Lombardo (GEL) carried out a study on 361 incident hepatocellular carcinoma observed from January to December 1998 in 22 hospitals in Lombardy. The clinical, pathological and therapeutic data were collected from all patients; 5-year survival and factors related to outcome were analysed. Results. Two hundred and ninety-seven patients were male (M[F: 4.6/1, mean age 66); 61% were HCV-pos, 15% HBV-pos, 17% alcoholic. Cirrhosis was present in 333 (92%) and was classified as Child-A in 197 (59%), Child-B in 85 (26%) and Child-C in 51 (15%) cases. Hepatocellular carcinoma was multifocal/diffuse (more than three nodules) in 91 (25%), less than three nodules in 86 (24%) and monofocal in 184 (51 %) (,= 3 cm in 146). As to the therapy: 145 hepatocellular carcinomas (40%) were ...
RESULTS: Seven patients (median age 21 years, range 19 - 42, 5 men, 2 women) underwent surgery for FLC. No patient had underlying liver disease or an elevated alpha feto-protein (AFP) at either initial presentation or recurrence. Six patients had a solitary tumour at diagnosis (mean largest diameter = 12cm), and underwent left hepatectomy (N=2), right hepatectomy (N=1), extended right hepatectomy (N=1), and segmentectomies (N=2). Three patients underwent a portal lymphadenectomy for regional lymphatic tumour involvement. One patient with advanced extrahepatic portal nodal metastasis was unresectable. No peri-operative deaths occurred. Recurrence occurred post resection in all 6 patients. Median overall survival was 60 months, and overall 5-year survival was 4 out of 7 (57%). Post-resection survival (N=6) was 61 months, with a 5-year survival rate of 4 out of 6 (67%). The patient with unresectable disease survived 38 months after tumour embolisation with Lipiodol ...
Hepatocellular carcinoma is considered to be the fifth most common cancer worldwide. Resection and liver transplantation have a high survival in the correct clinical scenarios; however, locoregional therapy has many advantages over tumor resection like preservation of hepatic parenchyma and overall less morbidity and mortality. Our aim was to present the role of dynamic subtraction MRI technique in the assessment of treatment response of hepatocellular carcinoma to transarterial chemoembolization. The study consisted of 43 patients with 55 hepatocellular carcinoma lesions who underwent transarterial chemoembolization procedure and followed up by dynamic MRI of the liver with post processing to obtain subtraction images 1-1.5 months after the procedure. If no signs of disease activity, another follow up study was preformed 2-4 months later. Five patients were excluded due to misregistration artifact at the subtraction images. The final cohort is 38 patients having 50 lesions. Precontrast T1, T2, dynamic
C7 peptide inhibits hepatocellular carcinoma metastasis by targeting the HGF/c-Met signaling pathway.: Hepatocellular carcinoma (HCC), characterized by a high r
Purpose: Early recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT) carries a poor prognosis. We aimed to develop a risk score for early HCC recurrence using pre-LT variables.. *Methods: Adults undergoing LT for HCC from 2001-2015 from 6 large centers were reviewed. Competing risk regression was used to identify predictors of early HCC recurrence (≤ 1 year).. *Results: Of 3235 patients, 459 developed HCC recurrence (14.2%), including 175 (38%) recurrences within 1 year of LT. Independent pre-LT predictors of early HCC recurrence included initial tumor size > 3 cm, ≥ 3 pre-LT locoregional therapies, pre-LT neutrophil-to-lymphoycte ratio > 5, and alpha-fetoprotein response. The early recurrence risk score was created using hazard ratios and resulted in low (0 points), low-medium (2-4 points), medium-high (5-8 points), and high (>8 points) risk groups (Fig 1). The probability of recurrence at 1-year in the low-risk group was 1.8% vs. 44.9% in the high-risk group ( ...
TY - JOUR. T1 - Increased Regulatory T Cells Correlate With CD8 T-Cell Impairment and Poor Survival in Hepatocellular Carcinoma Patients. AU - Fu, Junliang. AU - Xu, Dongping. AU - Liu, Zhenwen. AU - Shi, Ming. AU - Zhao, Ping. AU - Fu, Baoyun. AU - Zhang, Zheng. AU - Yang, Huiyin. AU - Zhang, Hui. AU - Zhou, Chunbao. AU - Yao, Jinxia. AU - Jin, Lei. AU - Wang, Huifen. AU - Yang, Yongping. AU - Fu, Yang Xing. AU - Wang, Fu Sheng. PY - 2007/6. Y1 - 2007/6. N2 - Background & Aims: Recent studies have suggested that CD4+CD25+ regulatory T cells (Treg) are increased and linked to compromised immune responses in patients with hepatocellular carcinoma (HCC). This study attempted to further characterize CD4+CD25+ forkhead/winged helix transcription factor (FoxP3)+ Treg in blood, tumor, and nontumor liver tissues of HCC patients, and to understand how the Treg affects immune responses and contributes to disease progression. Methods: A total of 123 HCC patients with chronic hepatitis B virus (HBV) ...
Fibrolamellar hepatocellular carcinoma (FL-HCC) is generally a fairly rare event in routine pathology practice. This variant of hepatocellular carcinoma (HCC) is peculiarly intriguing and,in addition, poorly understood. Young people or children are often the target individuals with this type of cancer. Previously, I highlighted some pathology aspects of FL-HCC, but in this review, the distinctive clinico-pathologic features of FL-HCC and the diagnostic pathologic criteria of FL-HCC are fractionally reviewed and expanded upon. Further, molecular genetics update data with reference to this specific tumor are particularly highlighted as a primer for general pathologists and pediatric histopathologists. FL-HCC may present with metastases, and regional lymph nodes may be sites of metastatic spread. However, peritoneal and pulmonary metastatic foci have also been reported. To the best of our knowledge, FL-HCC was initially considered having an indolent course, but survival outcomes have recently been updated
Recurrent hepatocellular carcinoma (HCC) with a tumor thrombus (TT) extending into the inferior vena cava (IVC)/right atrium (RA) is generally regarded as a terminal-stage condition and there is no worldwide consensus on the proper management of this situation. In the present study, we report the efficacy of hypofractionated radiotherapy (HFRT) as a salvage treatment for recurrent HCC with IVC/RA TT. We retrospectively reviewed 75 HCC patients with an IVC/RA TT who were referred for HFRT at three institutions between 2008 and 2016. 57 cases had a TT located in the IVC (IVC group), and 18 cases had a TT located in the IVC and RA (IVC + RA group). HFRT was designed to focus on the TT with or without the primary intrahepatic tumors. In all cases, the TT completely disappeared (CR) in 17 patients (22.7%), 55 patients (73.3%) had a partial response (PR), and 3 patients (4.0%) had a stable disease (SD). There were no cases of progressive disease (PD). The 1-, 2-, and 3-year overall survival rates of the 75
CD80 transfected human hepatocellular carcinoma cells activate cytotoxic T lymphocytes to target HCC cells with shared tumor antigens
We read with interest the article by Bruix et al1 in which Sorafenib was regarded as the standard treatment for hepatocellular carcinoma (HCC) patients with portal vein tumour thrombosis (PVTT). However, Sorafenib can only confer 2-3 months of overall survival (OS) benefit2 ,3 and is inapplicable to many patients due to extensive side effects and high price. Zhong et al4 proposed that liver resection might provide survival benefit to patients with HCC-PVTT with adequate liver function. However, this proposal was based on literature survey, lacked definite patient inclusion criteria and failed to provide information on patients baseline characteristics. Therefore, explorations of alternative therapeutics for patients with HCC-PVTT are still needed.. Although not recommended by mainstream guidelines5 ,6 for patients with HCC-PVTT, transarterial chemoembolisation (TACE) has long been practiced in the clinic in selected patients with HCC-PVTT.7 ,8 Gamma knife surgery (GKS) has shown favourable ...
Liver Cancer (hepatocellular carcinoma). Medical Term: None Specified. Description:. A malignant tumor arising from liver cells. Although much less common than metastatic liver cancer in most areas of the world, hepatocellular carcinoma is the most common internal malignancy and an important cause of death in certain areas of Africa and Southeast Asia. This is mainly because of the high incidence of Hepatitis B in these areas.. In North America, hepatocellular carcinoma is mainly associated with cirrhosis of the liver.. Causes: Unknown. As noted above, there is a high association with Hepatitis B and C, and cirrhosis of liver.. Prevention: Hepatitis B vaccination and prevention education for high-risk individuals. Minimize alcohol use.. Signs & Symptoms. ...
1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557-2576 2. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol. 2001;2:533-543 3. Bruix J, Sherman M. Management of hepatocellular carcinoma: An update. Hepatology. 2011;53:1020-1022 4. Wilhelm SM, Carter C, Tang L. et al. BAY 43-9006 exhibits broad spectrum oral anticancer activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64:7099-7109 5. Chang YS, Adnane J, Trail PA. et al. Sorafenib (BAY 43-9006) inhibits tumor growth and vasculization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol. 2007;59:561-574 6. Llovet JM, Ricci S, Mazzaferro V. et al. for the SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378-390 7. Cheng AL, Kang YK, Chen Z. et al. Efficacy and safety of ...
MicroRNAs (miRNAs) belong to the subgroup of small noncoding RNAs, which typically serve as important gene regulators to participate in different biological events, such as tumor cell growth and apoptosis. Recent studies indicated microRNA-4651 (miR-4651) was involved in hepatocellular carcinoma (HCC) progression. The certain role of miRNA-4651 during the progression of HCC, however, remains unclear. Herein, we investigated the mRNA expression level of miR-4651 in HCC tissues and HCC cell lines and found miR-4651 was noticeably downregulated compared with the normal liver tissues and QSG-7701 cell line, respectively. Then, miR-4561 overexpression obviously repressed the proliferation and promoted apoptosis in two HCC cell lines. Interestingly, we further identified that miR-4561 could directly interact with FOXP4 in HCC cells by using bio-informatic method and report assay. Moreover, forced expression of FOXP4 showed an opposite effect compared with miR-4561 in HCC cell lines. Hence, our ...
This trial assessed the efficacy and safety of sorafenib in advanced hepatocellular carcinoma patients in SEER-Medicare Database. The study determined the
Merkel-cell carcinoma. RNA virus. HCV Hepatocellular carcinoma. Splenic marginal zone lymphoma. HTLV-I Adult T-cell leukemia/ ... Hepatocellular carcinoma. HPV Cervical cancer. Anal cancer. Penile cancer. Vulvar cancer. Vaginal cancer. Oropharyngeal cancer ... El-Serag HB (22 September 2011). "Hepatocellular carcinoma". New England Journal of Medicine. 365 (12): 1118-27. doi:10.1056/ ... This type of infection dramatically increases the incidence of hepatocellular carcinoma (HCC; liver cancer). Across Europe, ...
... leading to hepatocellular carcinoma (autopsy specimen) However, cirrhosis is defined by its pathological features on ... Ultrasound may also screen for hepatocellular carcinoma, and portal hypertension, by assessing flow in the hepatic vein. An ... Forner A, Llovet JM, Bruix J (2012). "Hepatocellular carcinoma". The Lancet. 379 (9822): 1245-1255. doi:10.1016/S0140-6736(11) ... Singal AG, Pillai A, Tiro J (2014). "Early detection, curative treatment, and survival rates for hepatocellular carcinoma ...
and hepatocellular carcinoma. More recently, the Disney group further used their prediction database INFORNA to design ... "Small Molecule Targeting of a MicroRNA Associated with Hepatocellular Carcinoma". ACS Chemical Biology. 11 (2): 375-80. doi: ...
... of hepatocellular carcinoma (HCC). Men with chronic HCV or HBV are more likely to develop hepatocellular carcinoma than women ... "Hepatocellular carcinoma: a review". Journal of Hepatocellular Carcinoma. 3: 41-53. doi:10.2147/JHC.S61146. ISSN 2253-5969. PMC ... For example, it is recommended that people with chronic liver disease who are at risk for hepatocellular carcinoma be screened ... Hepatocellular carcinoma is associated with abdominal mass, abdominal pain, emesis, anemia, back pain, jaundice, itching, ...
Journal of Hepatocellular Carcinoma. 2: 57-68. doi:10.2147/JHC.S80756. PMC 4918285. PMID 27508195. Yu, Baofa; Lu, Yuanfei; Gao ... Journal of Hepatocellular Carcinoma. 2: 57-68. doi:10.2147/JHC.S80756. PMC 4918285. PMID 27508195. "Hospital offers service to ... "Hapten-enhanced overall survival time in advanced hepatocellular carcinoma by ultro-minimum incision personalized intratumoral ... "Hapten-enhanced overall survival time in advanced hepatocellular carcinoma by ultro-minimum incision personalized intratumoral ...
Pang RW, Joh JW, Johnson PJ, Monden M, Pawlik TM, Poon RT (April 2008). "Biology of hepatocellular carcinoma". Annals of ... Abnormal expression of glypicans has been noted in multiple types of cancer, including human hepatocellular carcinoma, ovarian ... "A Frizzled-Like Cysteine-Rich Domain in Glypican-3 Mediates Wnt Binding and Regulates Hepatocellular Carcinoma Tumor Growth in ... while GPC3 expression occurs in the majority of human hepatocellular carcinomas. A similar correlation has been found in ...
"Hepatocellular Carcinoma EASL Guideline". EASL-The Home of Hepatology. "Management of Alcohol-Related Liver Disease". EASL-The ...
CS1 maint: discouraged parameter (link) Behne, Tara; Copur, M. Sitki (1 January 2012). "Biomarkers for Hepatocellular Carcinoma ... a marker indicating a patient's non-small-cell lung carcinoma (NSCLC) will likely respond to gefitinib or erlotinib treatment. ... "Distinguishing second primary tumors from lung metastases in patients with head and neck squamous cell carcinoma". Journal of ... "Viral oncoprotein antibodies as a marker for recurrence of Merkel cell carcinoma: A prospective validation study". Cancer. 123 ...
Morgan TR, Mandayam S, Jamal MM (November 2004). "Alcohol and hepatocellular carcinoma". Gastroenterology. 127 (5 Suppl 1): S87 ... Voigt MD (February 2005). "Alcohol in hepatocellular cancer". Clin Liver Dis. 9 (1): 151-69. doi:10.1016/j.cld.2004.10.003. ... especially with respect to squamous cell carcinoma of the esophagus, oropharyngeal cancer, and breast cancer. Acetaldehyde, a ... day observed that this level of alcohol consumption was still associated with some elevated risk for squamous cell carcinoma of ...
Merkel-cell carcinoma. RNA virus. HCV Hepatocellular carcinoma. Splenic marginal zone lymphoma. HTLV-I Adult T-cell leukemia/ ... Hepatocellular carcinoma. HPV Cervical cancer. Anal cancer. Penile cancer. Vulvar cancer. Vaginal cancer. Oropharyngeal cancer ... Beasley RP, Hwang LY, Lin CC, Chien CS (November 1981). "Hepatocellular carcinoma and hepatitis B virus. A prospective study of ... The hepatitis B vaccine is the first vaccine that has been established to prevent cancer (hepatocellular carcinoma) by ...
A technique called radioembolization is used to treat hepatocellular carcinoma and liver metastasis. Radioembolization is a low ... Also see Radioembolization in the case of combined cirrhosis and Hepatocellular carcinoma. ... "Chemoembolization and Radioembolization for Hepatocellular Carcinoma". Clinical Gastroenterology and Hepatology. 11 (6): 604- ...
FDA Approval letter for use of sorafenib in inoperable hepatocellular carcinoma *^ a b "Liver drug 'too expensive'". BBC News. ... Along with renal cell carcinoma, hepatocellular carcinoma is one of the TGA-labelled indications for sorafenib.[10] ... hepatocellular carcinoma), FLT3-ITD positive AML and radioactive iodine resistant advanced thyroid carcinoma. ... 2008). "Sorafenib in Advanced Hepatocellular Carcinoma". New England Journal of Medicine. 359 (4): 378-90. CiteSeerX 10.1.1.531 ...
The presence of cirrhosis increases the risk of hepatocellular carcinoma. HHC is most common in certain European populations ( ... Kowdley, KV (November 2004). "Iron, hemochromatosis, and hepatocellular carcinoma". Gastroenterology. 127 (5 Suppl 1): S79-86. ...
Michielsen, Peter P; Francque, Sven M; Van Dongen, Jurgen L (2005). "Viral hepatitis and hepatocellular carcinoma". World ...
"Expression and processing of gastrin in patients with hepatocellular carcinoma, fibrolamellar carcinoma and cholangiocarcinoma ... Carr, Brian I; Pancoska, Petr; Branch, Robert A (2010-02-25). "Low alpha-fetoprotein hepatocellular carcinoma". Journal of ... be improved by measuring hPG80 levels as a complementary blood biomarker in a cohort of patients with hepatocellular carcinoma ... It has been observed that hPG80 concentrations are increased in patients at risk of developing colorectal carcinoma. In ...
Mallory bodies in hepatocellular carcinoma. Trichrome stain. "Cell Injury". Denk, H; Franke, WW; Eckerstorfer, R; Schmid, E; ... hepatocellular carcinoma (23%) and morbid obesity (8%), among other conditions. However, it has also been reported in certain ...
Michielsen, Peter P; Francque, Sven M; Van Dongen, Jurgen L (2005). "Viral hepatitis and hepatocellular carcinoma". World ... H Salim, Omer E; Hamid, Hytham K S; Mekki, Salwa O; Suleiman, Suleiman H; Ibrahim, Shakir Z (2010). "Colorectal carcinoma ... February 2012). "Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma". Genome Research. 22 (2): 299- ...
"Malignant transformation of hepatocellular adenomas into hepatocellular carcinomas: a systematic review including more than ... but the best available data suggests that the risk of hepatocellular adenoma becoming hepatocellular carcinoma, which is ... Transformation to hepatocellular carcinoma is more common in men. Currently, if the hepatic adenoma is >5 cm, increasing in ... Zhao YJ, Ju Q, Li GC (2013). "Tumor markers for hepatocellular carcinoma". Mol Clin Oncol. 1 (4): 593-598. doi:10.3892/mco. ...
"Orbital metastasis from hepatocellular carcinoma". Surv Ophthalmol. 50 (5): 485-9. doi:10.1016/j.survophthal.2005.06.014. PMID ... Honavar SG (2018). "Sebaceous gland carcinoma: Can we do better?". Indian J Ophthalmol. 66 (9): 1235-1237. doi:10.4103/ijo.IJO_ ... Mulay K, White VA, Shah SJ, Honavar SG (2014). "Sebaceous carcinoma: clinicopathologic features and diagnostic role of ... "Adenoid cystic carcinoma of the lacrimal gland: role of nuclear survivin (BIRC5) as a prognostic marker". Histopathology. 62 (6 ...
"Activin and follistatin in liver biology and hepatocellular carcinoma". SciTopics. Elsevier. Archived from the original on 9 ... "Activins and activin antagonists in hepatocellular carcinoma". World Journal of Gastroenterology. 14 (11): 1699-709. doi: ...
"Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC) - Full Text View ... The most common indication is for treatment of unresectable liver cancer (hepatocellular carcinoma). Transarterial ... Salem, Riad; Lewandowski, Robert J. (June 2013). "Chemoembolization and radioembolization for hepatocellular carcinoma". ... primary liver tumors such as hepatocellular carcinoma or cholangiocarcinoma and liver metastases are often treated by ...
... renal cell carcinoma, and hepatocellular carcinoma. It is a small molecule inhibitor of the tyrosine kinases c-Met and VEGFR2, ... In January 2019, the FDA approved cabozantinib (Cabometyx, Exelixis, Inc.) for people with hepatocellular carcinoma (HCC) who ... "FDA approves cabozantinib for hepatocellular carcinoma". U.S. Food and Drug Administration (FDA). 14 January 2019. Retrieved 23 ... vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib (CELESTIAL)" at ClinicalTrials.gov ...
Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22,707 men in Taiwan. Lancet 1981;2(8256):1129-1133 " ... His longitudinal observations were the first to demonstrate that hepatocellular carcinoma was prevented in Taiwanese males by ... making hepatocellular carcinoma and cirrhosis of the liver-one of the primary causes of death for much of the developing world ... cirrhosis and hepatocellular carcinoma." Dr. Beasley "demonstrated the efficacy of hepatitis B immune globulin in blocking ...
2015). "Poly(vinyl alcohol)/gelatin Hydrogels Cultured with Hep G2 Cells as a 3D Model of Hepatocellular Carcinoma: A ... Fanelli, Alex (2016). "HepG2 (liver hepatocellular carcinoma): cell culture". Retrieved 3 December 2017. Mersch-Sundermann, V ... 1975 from the liver tissue of a 15-year-old Caucasian male from Argentina with a well-differentiated hepatocellular carcinoma. ... 1979). "Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line". Nature. 282 (5739): 615-616 ...
Although this agent was the clear cause of hepatitis and might contribute to liver cancer hepatocellular carcinoma, this link ... Beasley RP, Hwang LY, Lin CC, Chien CS (November 1981). "Hepatocellular carcinoma and hepatitis B virus. A prospective study of ... The hepatitis B vaccine is the first vaccine that has been established to prevent cancer (hepatocellular carcinoma) by ... HCV was subsequently shown to be a major contributor to Hepatocellular carcinoma (liver cancer) worldwide. In 1994 Patrick S. ...
On 10 May 2019, ramucirumab was approved by FDA as a single agent treatment for hepatocellular carcinoma (HCC) in patients who ... Research, Center for Drug Evaluation and (2019-05-10). "FDA approves ramucirumab for hepatocellular carcinoma". FDA. "Cyramza: ... Levitan D (February 2016). "Added to Docetaxel Extends PFS in Urothelial Carcinoma". Cancer Network. Clinical trial number ... with metastatic colorectal carcinoma (CRC) progressive during or following first-line combination therapy with bevacizumab (bev ...
"Hepatitis C virus infection is associated with the development of hepatocellular carcinoma". Proc. Natl. Acad. Sci. USA. 87 (17 ... "Hepatitis C HCV associated hepatocellular carcinoma". Hepatology. 10 (4): 589-91. doi:10.1002/hep.1840100432. PMID 2169456. De ...
... and EMT interactions may also play a role in hepatocellular carcinoma. VEGF-B treatment of hepatoma carcinoma cells can ... In another example, Wnt/β-catenin signaling has been identified as activating microRNA-181s in hepatocellular carcinoma that ... Ji J, Yamashita T, Wang XW (2011). "Wnt/β-catenin signaling activates microRNA-181 expression in hepatocellular carcinoma". ... F9 embryonal carcinoma cells are similar to the P19 cells shown in Figure 1 and normally have cell-to-cell adhesion mediated by ...
Rudnick DA, Perlmutter DH (September 2005). "Alpha-1-antitrypsin deficiency: a new paradigm for hepatocellular carcinoma in ...
Hepatocellular carcinoma (HCC): Wagonjwa ambao hupatwa na kansa hii kwa kawaida ni katika idadi ya watu wadogo. Uvimbe huu pia ...
Merkel-cell carcinoma. RNA virus. HCV Hepatocellular carcinoma. Splenic marginal zone lymphoma. HTLV-I Adult T-cell leukemia/ ... Hepatocellular carcinoma. HPV Cervical cancer. Anal cancer. Penile cancer. Vulvar cancer. Vaginal cancer. Oropharyngeal cancer ...
Hepatocellular carcinoma. *Hodgkin's lymphoma. *Hypopharyngeal cancer. K. *Kaposi's sarcoma. L. *Laryngeal cancer ...
... including hepatocellular carcinoma,[27] an acceleration of age-related muscle mass loss,[28] an earlier incidence of cataracts ... and inactivation of SOD1 causes hepatocellular carcinoma.[27] Mutations in SOD1 can cause familial ALS (several pieces of ...
Gankyrin is anti-apoptotic and has been shown to be overexpressed in some tumor cell types such as hepatocellular carcinoma.[81 ...
"Global Burden of Aflatoxin-Induced Hepatocellular Carcinoma: A Risk Assessment". Environmental Health Perspectives. 118 (6): ...
It is expressed in embryonal carcinoma but not in seminoma and is thus a useful marker in distinguishing between these germ ... Hepatocellular carcinoma. *Alpha-fetoprotein/AFP-L3. Reproductive/. urinary/. breast. Ovarian tumor. *Surface epithelial- ...
"Evidence for the stem cell origin of hepatocellular carcinoma and cholangiocarcinoma". American Journal of Pathology. 134 (6): ... is useful in the diagnosis and may be used to help differentiate a cholangiocarcinoma from hepatocellular carcinoma and ... Roskams T (June 2006). "Liver stem cells and their implication in hepatocellular and cholangiocarcinoma". Oncogene. 25 (27): ... Henson DE, Albores-Saavedra J, Corle D (September 1992). "Carcinoma of the extrahepatic bile ducts. Histologic types, stage of ...
Diseases associated with this genus include: hepatitis, hepatocellular carcinomas (chronic infections), cirrhosis. Group: ssRNA ...
Diseases associated with this family include: liver infections, such as hepatitis, hepatocellular carcinomas (chronic ...
Celiac disease Ulcerative colitis Crohn's disease Hepatic cirrhosis Hepatocellular carcinoma Lung cancer, including small cell ... Wilkinson DS (1973). "Necrolytic migratory erythema with carcinoma of the pancreas". Transactions of the St. John's Hospital ...
malignant: Hepatocellular carcinoma *Fibrolamellar. *Hepatoblastoma. *benign: Hepatocellular adenoma. *Cavernous hemangioma. * ... The term 'crypt cell carcinoma' has been used for them, and though perhaps more accurate than considering them carcinoids, has ... "carcinoma-like", to describe the unique feature of behaving like a benign tumor despite having a malignant appearance ...
... and guidelines for the use of the BCLC staging system for diagnosing and monitoring hepatocellular carcinoma in Canada.[63] ... "Multidisciplinary Canadian Consensus Recommendations for the Management and Treatment of Hepatocellular Carcinoma'". Current ...
Liver Acute hemorrhage into a hepatocellular carcinoma causes severe upper right quadrant pain, and may be life-threatening, ... most often non-small-cell lung carcinoma (50 percent), small-cell lung carcinoma (25 percent), lymphoma, or metastasis, causing ...
Some carcinomas are named for their or the putative cell of origin, (e.g.hepatocellular carcinoma, renal cell carcinoma). ... In some types of carcinomas, Stage 0 carcinoma has been used to describe carcinoma in situ, and occult carcinomas detectable ... Carcinoma In situ[edit]. The term carcinoma in situ (or CIS) is a term for cells that are significantly abnormal but not cancer ... and sarcomatoid carcinoma (mixtures of spindle and giant cell carcinoma). Pleomorphic carcinoma contains spindle cell and/or ...
"DNA binding protein A expression and methylation status in hepatocellular carcinoma and the adjacent tissue. ". Int J Oncol. ... "Validation of housekeeping gene and impact on normalized gene expression in clear cell renal cell carcinoma: critical ...
... hepatocellular carcinoma) and human T-cell leukemia virus-1 (T-cell leukemias). Bacterial infection may also increase the risk ... Cancers are usually named using -carcinoma, -sarcoma or -blastoma as a suffix, with the Latin or Greek word for the organ or ... For example, the most common type of breast cancer is called ductal carcinoma of the breast. Here, the adjective ductal refers ... Carcinoma: Cancers derived from epithelial cells. This group includes many of the most common cancers and include nearly all ...
... hepatocellular carcinoma, pancreatic cancer), ovarian, hematologic or lung malignancies. ...
It has been shown that conserved miR-181 family were upregulated in EpCAM+ AFP+ Hepatocellular carcinoma (HCC) cells and EpCAM+ ... It was found that miR-181a and miR-181c are overexpressed in Papillary Thyroid Carcinoma tumors, sufficiently to successfully ... Mir-210 has been suggested as a useful biomarker to distinguish adrenocortical carcinoma from adrenocortical adenoma. in ... "The role of microRNA genes in papillary thyroid carcinoma". Proceedings of the National Academy of Sciences of the United ...
... enhances Wnt signaling and is over-expressed in hepatocellular carcinoma". Hepatology. 38 (1): 178-86. doi:10.1053/jhep. ... Inactivation of CDH1 (accompany with loss of the wild-type allele) in 56% of lobular breast carcinomas.[54][55] ... Inactivation of CDH1 in 50% of diffuse gastric carcinomas.[56]. *Complete loss of E-cadherin protein expression in 84% of ... Wang HD, Ren J, Zhang L (November 2004). "CDH1 germline mutation in hereditary gastric carcinoma". World Journal of ...
"Advanced Hepatocellular Carcinoma: Early Evaluation of Response to Bevacizumab Therapy at Dynamic Contrast-enhanced US with ... "Hepatocellular carcinoma treated with sorafenib: Early detection of treatment response and major adverse events by contrast- ...
"Alcohol and hepatocellular carcinoma". Gastroenterology 127 (5 Suppl 1): S87-96. doi:10.1053/j.gastro.2004.09.020 . PMID ... "Alcohol in hepatocellular cancer". Clin Liver Dis 9 (1): 151-69. doi:10.1016/j.cld.2004.10.003 . PMID 15763234 . http:// ...
en:Hepatocellular carcinoma (27) → 간세포암 *en:Herpes labialis (25). *en:Hiatal hernia (29) ...
malignant: Hepatocellular carcinoma *Fibrolamellar. *Hepatoblastoma. *benign: Hepatocellular adenoma. *Cavernous hemangioma. * ...
... are dysregulated in human hepatocellular carcinoma and linked to the malignant phenotype of tumors". Oncogene. 25 (45): 6056-66 ...
RFA may be combined with locally delivered chemotherapy to treat hepatocellular carcinoma (primary liver cancer). A method ... in Treatment of Hepatocellular Carcinoma (HCC) Hadjicostas, P.; Malakounides, N.; Varianos, C.; Kitiris, E.; Lerni, F.; ... drugs from heat-sensitive liposomes in the margins around the ablated tissue as a treatment for Hepatocellular carcinoma (HCC ...
Anticancer effects of the Chinese medicine matrine on murine hepatocellular carcinoma cells. Planta Med 74:245-251 ...
... hepatocellular carcinoma), ଏବଂ ହ୍ୟୁମ୍ୟାନଟି ସେଲ ଲିଉକେମିଆ ଭୂତାଣୁ - ୧ - (ଟି ସେଲ ଲିଉକେମିଆ) । ଜୀବାଣୁ ସଂକ୍ରମଣର ଉଦାହରଣ - ... A squamous-cell carcinoma (the whitish tumor) near the bronchi in a lung specimen ... cervical carcinoma), ଏବସଟେନ ବାର ଭୂତାଣୁ (Epstein-Barr virus) - (ବି ସେଲ ଲିମ୍ଫୋପ୍ରୋଲିଫରେଟିଭ ରୋଗ) (B-cell lymphoproliferative ... disease) ଓ ନାଜୋଫାରିଞ୍ଜିଆଲ କାରସିନୋମା (nasopharyngeal carcinoma), କାପୋଷି ସାରକୋମା ହର୍ପିସ ଭୂତାଣୁ (କାପୋଷି ସାରକୋମା ଓ ପ୍ରାଥମିକ ଇଫ୍ୟୁଜନ ...
"Lymphoepithelioma-like hepatocellular carcinoma: an uncommon variant of hepatocellular carcinoma with favorable outcome". Am J ... Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer in adults and is currently the most common cause ... The risk of hepatocellular carcinoma in type 2 diabetics is greater (from 2.5 to 7.1 times the nondiabetic risk) depending on ... Hepatocellular carcinoma (Photo) ATLAS OF PATHOLOGY Chan AW, Zhang Z, Chong CC, Tin EK, Chow C, Wong N (2019). "Genomic ...
Fibrolamellar hepatocellular carcinoma (FHCC) is a rare form of hepatocellular carcinoma (HCC) that typically affects young ... Lafaro KJ, Pawlik TM (2015) Fibrolamellar hepatocellular carcinoma: current clinical perspectives. J Hepatocell Carcinoma 2:151 ... The name fibrolamellar hepatocellular carcinoma was coined by Craig et al. in 1980. It was not recognised as a distinct form of ... 2009). "Fibrolamellar hepatocellular carcinoma- report of a case". Chang Gung Med J. 32 (3): 336-9. PMID 19527614. ...
... characterization and novel gene-isolation techniques have vigorously expanded our understanding of hepatocellular carcinoma ( ... In Hepatocellular Carcinoma: Methods and Protocols, Nagy Habib and a team of basic and clinical researchers describe the wide ... Hepatocellular Carcinoma: Methods and Protocols offers experimental and clinical investigators a rich source of both basic ... Measurement of Protein Expression of p53, p21WAF1, and Rb in Patients with Surgically Treated Hepatocellular Carcinoma by Using ...
This year the number of papers published regarding hepatocellular carcinoma (HCC) continued to increase compared with last year ...
... Liver cancer, primarily hepatocellular carcinoma (HCC), is the third ... Decreased incidence of hepatocellular carcinoma in hepatitis B vaccines: a 20-year follow-up study. J Natl Cancer Inst 2009;101 ... Hepatocellular carcinoma (HCC) is a leading cause of cancer deaths in the United States and worldwide; infection with hepatitis ... Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009;27 ...
The most common form of liver cancer in adults is hepatocellular carcinoma. Learn about diagnosis, treatment and taking part in ... ClinicalTrials.gov: Carcinoma, Hepatocellular (National Institutes of Health) * ClinicalTrials.gov: Hepatoblastoma (National ... Article: Risk factors of infection after transarterial chemoembolization for hepatocellular carcinoma: A... ... Liver (Hepatocellular) Cancer Screening (PDQ)-Patient Version (National Cancer Institute) Also in Spanish ...
Focus on hepatocellular carcinoma.. Bruix J1, Boix L, Sala M, Llovet JM. ...
... and prognostic impact of metastasis in hepatocellular carcinoma, proposing a modified BCLC system based on metastasis. ... Extrahepatic metastasis of hepatocellular carcinoma (HCC) is not uncommon. However, its prognostic effect is not fully studied. ... Hepatocellular carcinoma patients with metastasis at the time of diagnosis have shorter overall survival compared to patients ... Re-allocating 181 hepatocellular carcinoma (HCC) patients with a combination of vascular invasion and metastasis from Barcelona ...
Latest advances in external beam radiotherapy for hepatocellulalar carcinoma. Presented at Liver Disease awareness week 2014 ... External Beam Radiotherapy for Hepatocellular carcinoma * 1. Latest advances in radiotherapy for hepatocellular carcinoma Liver ... Latest advances in external beam radiotherapy for hepatocellulalar carcinoma. Presented at Liver Disease awareness week 2014 ...
... for hepatocellular carcinoma (HCC) in the United States in 1963. In the worlds first 7 LTs, 3 of them were performed for HCC ... Expanded criteria for hepatocellular carcinoma and liver transplantation. Transplant Proc, 2007, 39: 1171-1174.PubMedCrossRef ... Management of hepatocellular carcinoma in the waiting list before liver transplantation. J Hepatol, 2005, 42: S134-S143.PubMed ... Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. Transplantation, 2008, 85: 1726-1732.PubMedCrossRef ...
Hepatocellular carcinoma is the most common type of malignant liver cancer. Primary liver cancers are rare and the condition ... www.hopkinsmedicine.org/.../hepatocellular_carcinoma_liver_cancer.pdf. *www.worldgastroenterology.org/.../24_hepatocellular_ ... What are Hepatocellular Carcinomas?. News-Medical. https://www.news-medical.net/health/What-are-Hepatocellular-Carcinomas.aspx ... Hepatocellular carcinoma is the most common type of malignant liver cancer. Primary liver cancers are rare and the condition ...
Hepatocellular Carcinoma News and Research. RSS Hepatocellular Carcinoma is a type of adenocarcinoma, the most common type of ... Hepatocellular carcinoma is the most common form of liver cancer, and the third biggest cause of death from cancer worldwide. ... Patients with hepatocellular carcinoma (HCC) waiting for a liver transplant in the USA are now significantly less likely to ... New, sensitive HBV assay may allow earlier detection of hepatocellular carcinoma Chronic hepatitis B virus (HBV) can progress ...
... available data from published papers reporting various tissue and serum biomarkers involved in hepatocellular carcinoma was ... The hepatocellular carcinoma (HCC) is one of the most common malignant tumors and carries a poor survival rate. The management ... Biomarkers for Hepatocellular Carcinoma. Tara Behne1 and M. Sitki Copur1. ,. 2. 1College of Pharmacy, University of Nebraska ... Biomarkers for Hepatocellular Carcinoma,. International Journal of Hepatology,. vol. 2012. ,. Article ID 859076. ,. 7. pages. ...
... (HCC) is the fifth most common cause of cancer, and its incidence is increasing worldwide because of ... Hepatocellular carcinoma (HCC) is the fifth most common cause of cancer, and its incidence is increasing worldwide because of ... Hepatocellular carcinoma Lancet. 2003 Dec 6;362(9399):1907-17. doi: 10.1016/S0140-6736(03)14964-1. ...
Hepatocellular carcinoma (HCC) is a type of liver cancer. Its treated by a health care team of specialists in many areas. ... en españolCarcinoma hepatocelular. What Is Hepatocellular Carcinoma (HCC)?. Hepatocellular carcinoma (HCC) is a type of liver ... How Is Hepatocellular Carcinoma (HCC) Diagnosed?. When a child has hepatocellular carcinoma, the doctor will do an exam. Tests ... What Causes Hepatocellular Carcinoma (HCC)?. Doctors dont know the exact cause of hepatocellular carcinoma. Children who have ...
FDA approves cabozantinib for hepatocellular carcinoma Listen to the FDA D.I.S.C.O. podcast about this approval. ... for patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. ...
Hepatocellular carcinoma is cancer that starts in the liver. ... Hepatocellular carcinoma is not the same as metastatic liver ... Hepatocellular carcinoma accounts for most liver cancers. This type of cancer occurs more often in men than women. It is ... To accurately diagnose hepatocellular carcinoma, a biopsy of the tumor must be done. ...
Are patients with cirrhosis particularly vulnerable to developing hepatocellular carcinoma, and how should they be screened for ... Journal Article Risk of Hepatocellular Carcinoma in Non-alcoholic Steatohepatitis Without Cirrhosis Compared to Other Liver ... thus meeting the radiographic diagnosis criteria for hepatocellular carcinoma (HCC) of the American Association for the Study ... of Chronic Hepatitis C With Direct-acting Antivirals Does Not Change the Short-term Risk for De Novo Hepatocellular Carcinoma ...
Reptilase test in cirrhosis and hepatocellular carcinoma. Br Med J 1977; 2 :1544 ... Reptilase test in cirrhosis and hepatocellular carcinoma.. Br Med J 1977; 2 doi: https://doi.org/10.1136/bmj.2.6101.1544 ( ...
Hepatocellular carcinoma (HCC) - Learn about innovative treatment of HCC liver cancer, including liver transplant, ablation and ... Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer. Hepatocellular carcinoma occurs most often in ... Hepatocellular carcinoma treatments include:. *Surgery. Surgery to remove the cancer and a margin of healthy tissue that ... Which treatment is best for you will depend on the size and location of your hepatocellular carcinoma, how well your liver is ...
Finally, on the basis of a patient-derived tumour xenograft mouse model of hepatocellular carcinoma, we found that treatment ... Infection with the hepatitis B virus is one of the leading risk factors for developing hepatocellular carcinoma, particularly ... Our quantitative proteomic data highlight heterogeneity in early-stage hepatocellular carcinoma: we used this to stratify the ... The proteomic stratification of early-stage hepatocellular carcinoma presented in this study provides insight into the tumour ...
A Nigerian newspaper and Online version of the Vanguard, a daily publication in Nigeria covering Nigeria news, Niger delta, general national news, politics, business, energy, sports, entertainment, fashion,lifestyle human interest stories, etc. ...
Learn more about hepatocellular carcinoma, including its symptoms, risks, and treatment options. ... Diagnosing Hepatocellular Carcinoma. Symptoms of hepatocellular carcinoma. Many people with hepatocellular carcinoma (HCC) have ... Hepatocellular Carcinoma Overview. Hepatocellular carcinomas (HCC) are also known as primary liver cancers, hepatic tumors, or ... Testing for hepatocellular carcinoma. In addition to a physical exam, your doctor may order the following tests to help ...
Hepatocellular carcinoma (HCC) with a focus on diagnosis and screening. (Source: Notes from Dr. RW). Source: Notes from Dr. RW ... Rapid Hepatocellular Carcinoma Test Can be Administered Anywhere. Researchers at the University of Utah have developed a rapid ... Hepatocellular Carcinoma Blogs This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to ... Hepatocellular Carcinoma : Triple Phase CT. Presenting brief teaching video under the DAMS Unplugged series on HCC and imaging ...
... for patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. ... Adverse reactions occurring in patients with hepatocellular carcinoma were similar to those described in KEYTRUDA product ... The recommended pembrolizumab dose for hepatocellular carcinoma is 200 mg administered as an intravenous infusion over 30 ... for patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. ...
hepatocellular carcinoma synonyms, hepatocellular carcinoma pronunciation, hepatocellular carcinoma translation, English ... Noun 1. hepatocellular carcinoma - carcinoma of the liver hepatocarcinoma, hepatoma, malignant hepatoma carcinoma - any ... hepatocellular carcinoma - carcinoma of the liver hepatocarcinoma, hepatoma, malignant hepatoma. carcinoma - any malignant ... Hepatocellular Carcinoma - Pipeline Review, H1 2016, provides an overview of the Hepatocellular Carcinoma pipeline landscape. ...
For large hepatocellular carcinoma tumors, transarterial chemoembolization plus radiofrequency ablation improves survival ... Blood flow to hepatocellular carcinoma lesions can be substantially reduced by the arterial embolization effect of ... The 291 consecutive patients with hepatocellular carcinoma larger than 3 cm were randomly assigned to treatment with an ... In particular, neither results in adequate control of hepatocellular carcinoma tumors larger than 3 cm." ...
... miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma ... microvascular invasion in hepatocellular carcinoma promotes angiogenesis and serves as a predictor for hepatocellular carcinoma ... "H3K4 dimethylation in hepatocellular carcinoma is rare compared with other hepatobiliary and gastrointestinal carcinomas and ... New Insights into the Epigenetics of Hepatocellular Carcinoma. Braira Wahid,1 Amjad Ali,1 Shazia Rafique,1 and Muhammad Idrees1 ...
... represents an emerging cause of hepatocellular carcinoma (HCC), especially in non-cirrhotic individuals. The rs641738 C , T ... Table 5 Independent predictors of hepatocellular carcinoma (HCC) in 1121 non-cirrhotic patients with chronic liver diseases ... Risk of hepatocellular carcinoma according to the number of PNPLA3 I148M, TM6SF2 E167K, and MBOAT7 rs641738 C , T risk variants ... Table 2 Frequency distribution of PNPLA3, TM6SF2, and MBOAT7 variants according to hepatocellular carcinoma (HCC) in 765 ...
Current Treatments for Liver Cancer (also known as hepatoma or hepatocellular carcinoma) can result in complete cure of the ...
  • This year the number of papers published regarding hepatocellular carcinoma (HCC) continued to increase compared with last year, coinciding with an increase in incidence and awareness of this tumor. (nih.gov)
  • Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. (springer.com)
  • Tumor size predicts vascular invasion and histologic grade: implications for selection of surgical treatment for hepatocellular carcinoma. (springer.com)
  • Orthotopic liver transplantation for patients with hepatocellular carcinoma complicated by portal vein tumor thrombi. (springer.com)
  • Preoperative human-telomerase reverse transcriptase mRNA in peripheral blood and tumor recurrence in living-related liver transplantation for hepatocellular carcinoma. (springer.com)
  • Hepatocellular carcinoma (HCC) is one such cancer that can benefit from tumor biomarkers' diagnostic, therapeutic, and prognostic capabilities. (hindawi.com)
  • The first serologic assay for detection and clinical followup of patients with hepatocellular carcinoma was alpha-fetoprotein (AFP) which has been the standard tumor biomarker for HCC for many years. (hindawi.com)
  • To accurately diagnose hepatocellular carcinoma, a biopsy of the tumor must be done. (medlineplus.gov)
  • TriSalus, a Denver, Colorado firm, is launching a new solid tumor infusion system to target hepatocellular carcinoma, liver metastases, and other tumors. (medworm.com)
  • Here, we adopted a mouse model and metagenome sequencing to investigate the efficacy of probiotic feeding in controlling s.c. hepatocellular carcinoma (HCC) and the underlying mechanism suppressing the tumor progression. (pnas.org)
  • Hepatocellular carcinoma (HCC) is the most common primary liver tumor and results in approximately 700,000 deaths annually worldwide. (rarediseases.org)
  • Children with hepatocellular carcinoma are treated in the Liver Tumor Center at the Dana-Farber/Boston Children's Cancer and Blood Disorders Center. (childrenshospital.org)
  • AMA J Dis Child 91(2):168-186 Craig JR, Peters RL, Edmondson HA, Omata M. Fibrolamellar carcinoma of the liver: a tumor of adolescents and young adults with distinctive clinico-pathologic features. (wikipedia.org)
  • Hepatocellular carcinoma describes a rare but malignant tumor of the epithelial tissues of the liver (the tissue that lines the cavities and surfaces of body structures - in this case the liver). (petmd.com)
  • This type of tumor is rare in cats - cats are more commonly affected by bile duct carcinoma. (petmd.com)
  • Hepatocellular carcinoma (HCC) is a typical hypervascularized tumor, and the predictive value of MVD for prognosis is still controversial. (frontiersin.org)
  • MVD in multinodular hepatocellular carcinoma represents a subject area with huge understudied potential, and exploring it might advance our understanding of tumor heterogeneity. (frontiersin.org)
  • Hepatocellular carcinoma (HCC) is the most common primary malignant tumor of the liver and the third most common cause of cancer-related death worldwide. (renalandurologynews.com)
  • Doctors don't know the exact cause of hepatocellular carcinoma. (kidshealth.org)
  • Nonalcoholic fatty liver disease (NAFLD) represents an emerging cause of hepatocellular carcinoma (HCC), especially in non-cirrhotic individuals. (nature.com)
  • Geographically, the global Hepatocellular Carcinoma (HCC) treatment market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, APEJ, Japan, Middle East and Africa.Hepatitis B virus (HBV) infection and hepatitis C virus (HCV) infections are found to be the most significant cause of hepatocellular carcinoma. (openpr.com)
  • Chronic HBV infection is the principal cause of hepatocellular carcinoma in Asia and Africa. (openpr.com)
  • HCV infection is the principal cause of hepatocellular carcinoma in North America, Europe, and Japan. (openpr.com)
  • announced today that the results of an analysis of a Phase III trial (REFLECT study / Study 304)1 of its in-house discovered and developed anticancer agent lenvatinib mesylate (product names: Lenvima / Kisplyx, lenvatinib) versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma based on independent imaging review were presented2 during the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI) 2018, in San Francisco, the United States. (thefreedictionary.com)
  • The exact role for transarterial chemoembolization-radiofrequency ablation in the treatment of patients with unresectable hepatocellular carcinoma remains a controversial and unresolved issue," they wrote, "similar to the situation for many of the interventional-based therapies. (medpagetoday.com)
  • To assess the benefits and harms of immune checkpoint inhibitors versus placebo, no treatment, or other systemic or locoregional therapies for people with unresectable hepatocellular carcinoma. (cochrane.org)
  • Abdel-Rahman O, Elsayed Z. Immune checkpoint inhibitors for unresectable hepatocellular carcinoma. (cochrane.org)
  • Officials with the FDA have approved lenvatinib capsules (Lenvima, Eisai Inc.) for first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). (pharmacytimes.com)
  • FDA approves lenvatinib for unresectable hepatocellular carcinoma [news release]. (pharmacytimes.com)
  • Woodcliff Lake, NJ and Kenilworth, NJ, Aug. 16, 2018 - Eisai Inc. and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) approved the kinase inhibitor Lenvima ( lenvatinib ) for the first-line treatment of patients with unresectable hepatocellular carcinoma ( HCC ). (drugs.com)
  • Unresectable hepatocellular carcinoma is an extremely difficult-to-treat cancer, with no new first-line systemic therapy options for more than a decade," said Dr. Ghassan Abou-Alfa, medical oncologist, Memorial Sloan Kettering Cancer Center. (drugs.com)
  • Here, using proteomic and phospho-proteomic profiling, we characterize 110 paired tumour and non-tumour tissues of clinical early-stage hepatocellular carcinoma related to hepatitis B virus infection. (nature.com)
  • In all these articles, hepatocellular carcinoma was the most-discussed topic(19), followed by hepatitis B virus(8) and endoscopic(5). (thefreedictionary.com)
  • In order to determine whether EBV infection is associated with HCC, we examined paraffin-embedded tissues from 31 cases of non-cirrhotic livers with hepatocellular carcinoma for the presence of EBV, HCV and hepatitis B virus (HBV) infection. (nih.gov)
  • The risk factors associated with hepatocellular carcinoma are Hepatitis B virus (HBV) infection and hepatitis C virus (HCV) infection, alcoholic cirrhosis, metabolic syndrome, biliary cirrhosis, and chronic liver injury. (openpr.com)
  • Hepatocellular carcinoma (HCC) is the most prevalent primary liver cancer, and its incidence is increasing in different populations in recent decades, specifically in Asian countries due to hepatitis B virus infection. (frontiersin.org)
  • The technological advancements and the routine liver function tests are now resulting in the early detection of hepatocellular carcinoma. (openpr.com)
  • Most patients with chronic viral hepatitis are surveilled with ultrasound to aid in the detection of hepatocellular carcinoma. (knowcancer.com)
  • The development of hepatocellular carcinoma can disrupt these functions or even cause them to fail altogether. (news-medical.net)
  • A research team led by scientists from the Cancer Institute of Singapore at the National University of Singapore has developed a novel peptide drug called FFW that could potentially stop the development of hepatocellular carcinoma or primary liver cancer. (news-medical.net)
  • Recent studies suggest that Epstein-Barr virus (EBV) may act as a helper virus for the development of hepatocellular carcinoma by promoting replication of the hepatitis C virus (HCV) in the infected liver. (nih.gov)
  • Other unknown risk factors seem to be in effect in the development of hepatocellular carcinoma in non-cirrhotic livers. (nih.gov)
  • JINAN, China, April 8 -- For large hepatocellular carcinoma tumors, transarterial chemoembolization plus radiofrequency ablation improves survival better than either alone, according to researchers here. (medpagetoday.com)
  • Blood flow to hepatocellular carcinoma lesions can be substantially reduced by the arterial embolization effect of transcatheter arterial chemoembolization treatment. (medpagetoday.com)
  • As Clinical Markers, Hand-Foot-Skin Reaction and Diarrhea Can Predict Better Outcomes for Hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization plus Sorafenib. (medworm.com)
  • A subsequent triphasic abdominal computed tomography (CT) scan showed a 2.2-cm well-circumscribed vascular mass that had arterial enhancement and venous washout, thus meeting the radiographic diagnosis criteria for hepatocellular carcinoma (HCC) of the American Association for the Study of Liver Disease (AASLD). (medscape.com)
  • Objective: To determine the diagnostic accuracy of quantitative washout calculated on Triphasic CT scan for diagnosis of hepatocellular carcinoma keeping histopathology as gold standard. (thefreedictionary.com)
  • The diagnosis of hepatocellular carcinoma (HCC) in lobectomy specimens is usually straightforward, but distinguishing cirrhosis from well-differentiated HCC can be challenging in core biopsies. (thefreedictionary.com)
  • Presenting the most up-to-date knowledge of hepatocellular carcinoma, it covers all topics - including those more controversial ones - in this rapidly advancing field, from epidemiology to prevention, from molecular biology to gross pathology, from screening to atypical presentation, from diagnosis to treatment, and from assessment to choice of appropriate treatment. (ovid.com)
  • Is resection for large hepatocellular carcinoma in cirrhotic patients beneficial? (nii.ac.jp)
  • Starzl performed the world's first liver transplantation (LT) for hepatocellular carcinoma (HCC) in the United States in 1963. (springer.com)
  • The 11-year Pittsburgh experience with liver transplantation for hepatocellular carcinoma: 1981-1991. (springer.com)
  • Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. (springer.com)
  • Role of Pittsburgh modified TNM criteria in prognosis prediction of liver transplantation for hepatocellular carcinoma. (springer.com)
  • Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA. (springer.com)
  • Living donor liver transplantation of the right lobe for hepatocellular carcinoma in cirrhosis in a European center. (springer.com)
  • Sugawara Y, Tamura S, Makuuchi M. Living donor liver transplantation for hepatocellular carcinoma: Tokyo University series. (springer.com)
  • Expansion of selection criteria for patients with hepatocellular carcinoma in living donor liver transplantation. (springer.com)
  • Expanded indication criteria of living donor liver transplantation for hepatocellular carcinoma at one large-volume center. (springer.com)
  • Mak K S, Tan K C. Liver transplantation for hepatocellular carcinoma: an Asian perspective. (springer.com)
  • Busuttil R W. Liver transplantation for hepatocellular carcinoma: the Hangzhou experience. (springer.com)
  • Management of hepatocellular carcinoma in the waiting list before liver transplantation. (springer.com)
  • 2013. How to decide about liver transplantation in patients with hepatocellular carcinoma: size and number of lesions or response to TACE? (unimedizin-mainz.de)
  • The present invention provides a method for predicting prognosis of hepatocellular carcinoma patients based on measurement of the relative level of expression of a combination of 15 immune genes of interest, or a subset thereof, in the tumors of such patients. (freepatentsonline.com)
  • Although sorafenib enhances overall survival, sorafenib resistance has been reported to be a significant limiting factor for improved prognosis in patients with hepatocellular carcinoma (HCC). (bioportfolio.com)
  • Hepatocellular carcinoma (HCC) is an aggressive malignancy with a poor prognosis. (atlasgeneticsoncology.org)
  • Hepatocellular carcinoma (HCC) ranks among the most common malignancies worldwide, and the prognosis for patients with HCC is typically poor. (appliedradiology.com)
  • Epigenetic modulators and related molecular mechanisms are investigated in the context of chronic liver diseases and hepatocellular carcinoma (Marquardt J.U. Hepatology 2013). (unimedizin-mainz.de)
  • In Hepatocellular Carcinoma: Methods and Protocols, Nagy Habib and a team of basic and clinical researchers describe the wide variety of powerful new laboratory-based molecular methods currently being used for investigating and treating this disease. (springer.com)
  • Hepatocellular Carcinoma: Methods and Protocols offers experimental and clinical investigators a rich source of both basic science and clinical information on today's optimal use of gene therapy to treat and manage patients suffering from hepatocellular carcinoma. (springer.com)
  • Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today provided an update on its Phase II clinical trial with drug candidate Namodenoson in the treatment of advanced hepatocellular carcinoma in patients whose disease has progressed on sorafenib therapy. (news-medical.net)
  • Our quantitative proteomic data highlight heterogeneity in early-stage hepatocellular carcinoma: we used this to stratify the cohort into the subtypes S-I, S-II and S-III, each of which has a different clinical outcome. (nature.com)
  • Lafaro KJ, Pawlik TM (2015) Fibrolamellar hepatocellular carcinoma: current clinical perspectives. (wikipedia.org)
  • Respiratory-gated, volumetric-modulated arc therapy will be used for the clinical development of high dose rate Stereotactic Body Radiotherapy (SBRT) in inoperable hepatocellular carcinoma (HCC). (clinicaltrials.gov)
  • Boston, MA -- ( SBWIRE ) -- 04/30/2014 -- GlobalData's clinical trial report, "Metastatic Hepatocellular Carcinoma (HCC) Global Clinical Trials Review, H1, 2014" provides data on the Metastatic Hepatocellular Carcinoma (HCC) clinical trial scenario. (sbwire.com)
  • This report provides elemental information and data relating to the clinical trials on Metastatic Hepatocellular Carcinoma (HCC). (sbwire.com)
  • The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Metastatic Hepatocellular Carcinoma (HCC). (sbwire.com)
  • If diagnosed at an early stage, it may be possible to treat hepatocellular carcinoma. (news-medical.net)
  • Doctors usually treat hepatocellular carcinoma with a combination of surgery and chemotherapy . (kidshealth.org)
  • A retrospective review published in the American Journal of Roentgenology (AJR) has found that aspirin therapy is associated with both improved liver function test results and survival after transarterial embolization (TAE) for hepatocellular carcinoma (HCC). (pharmacytimes.com)
  • Advances in molecular characterization and novel gene-isolation techniques have vigorously expanded our understanding of hepatocellular carcinoma (HCC), a form of liver cancer that affects one million people annually, and generated many new therapeutic possibilities. (springer.com)
  • Hepatocellular carcinoma is the sixth most prevalent cancer and the third most frequent cause of cancer-related death. (nih.gov)
  • Findings of randomised trials of sorafenib have shown survival benefits for individuals with advanced hepatocellular carcinoma, suggesting that molecular-targeted therapies could be effective in this chemoresistant cancer. (nih.gov)
  • Liver cancer, primarily hepatocellular carcinoma (HCC), is the third leading cause of death from cancer worldwide and the ninth leading cause of cancer deaths in the United States ( 1,2 ). (cdc.gov)
  • Hepatocellular carcinoma is the most common type of malignant liver cancer. (news-medical.net)
  • My son was diagnosed with Hepatocellular-Carcinoma ( Liver cancer) when he was 15 and he has almost made his way to the 5 year mark, I worry about him everyday and hope he is in the clear! (news-medical.net)
  • Hepatocellular carcinoma is the most common form of liver cancer, and the third biggest cause of death from cancer worldwide. (news-medical.net)
  • Hepatocellular carcinoma (HCC) is the fifth most common cause of cancer, and its incidence is increasing worldwide because of the dissemination of hepatitis B and C virus infection. (nih.gov)
  • Hepatocellular carcinoma (HCC) is a type of liver cancer . (kidshealth.org)
  • Hepatocellular carcinoma is cancer that starts in the liver. (medlineplus.gov)
  • Hepatocellular carcinoma is not the same as metastatic liver cancer , which starts in another organ (such as the breast or colon) and spreads to the liver. (medlineplus.gov)
  • Hepatocellular carcinoma is the third leading cause of deaths from cancer worldwide. (nature.com)
  • The proteomic stratification of early-stage hepatocellular carcinoma presented in this study provides insight into the tumour biology of this cancer, and suggests opportunities for personalized therapies that target it. (nature.com)
  • The UPMC Liver Cancer Center's multidisciplinary team of experts offers several treatment options for people with hepatocellular carcinoma (HCC). (upmc.com)
  • It was reported on Friday that the contract has been signed to develop RX-0201 (Archexin) intended for the treatment of hepatocellular carcinoma , the most common form of liver cancer. (thefreedictionary.com)
  • Merck announced findings from the registrational phase 2 KEYNOTE-224 trial investigating the use of KEYTRUDA, the company's anti-PD-1 therapy, in patients with advanced hepatocellular carcinoma , the most common type of liver cancer, who were previously treated with systemic therapy. (thefreedictionary.com)
  • Current Treatments for Liver Cancer (also known as hepatoma or hepatocellular carcinoma) can result in complete cure of the disease if it is detected early. (medindia.net)
  • Hepatocellular carcinoma is the second most deadly cancer type globally, requiring the development of alternative or complementary therapeutic and prophylactic methods. (pnas.org)
  • The global hepatocellular carcinoma treatment market is expected to grow in future due to increasing investment by multinational companies in the cancer research. (openpr.com)
  • Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer in adults and is currently the most common cause of death in people with cirrhosis. (wikipedia.org)
  • Hepatocellular carcinoma , also called liver carcinoma, is a rare, aggressive type of liver cancer. (childrenshospital.org)
  • Primary liver cancer (hepatocellular carcinoma) is the fifth most common cause of cancer death in American men and the ninth most common cause of death in women. (northshore.org)
  • Alcohol-related cirrhosis and chronic hepatitis B or C infection contribute to the majority of liver cancer cases diagnosed in the U.S. Obesity and diabetes are also major factors in the rise of hepatocellular carcinoma. (northshore.org)
  • Hepatocellular carcinoma (HCC) is the most common primary liver cancer and accounts for about 6% of all new cancer cases worldwide. (europa.eu)
  • The current treatment guidelines of hepatocellular carcinoma (HCC) of the American and European Associations for the Study of Liver Disease are based on the Barcelona-Clinic-Liver-Cancer classification (BCLC), which does not recommend surgery in patients with large, multinodular and macrovascular invasive disease. (clinicaltrials.gov)
  • Hepatocellular carcinoma is a form of cancer that originates in hepatocytes. (microscopyu.com)
  • In the United States, hepatocellular carcinoma is relatively rare, but globally it is one of the leading causes of cancer-related death. (microscopyu.com)
  • Andrew Zhu, the lead trial investigator and head of liver cancer research at Massachusetts General Hospital , said hepatocellular carcinoma is the most common type of liver cancer in adults. (biospace.com)
  • We look forward to continuing to advance research for hepatocellular carcinoma across our portfolio with the goal to help even more patients affected by this type of cancer," Ebbinghaus said in a statement. (biospace.com)
  • Hepatocellular carcinoma (HCC) is a major type of primary liver cancer and one of the rare human neoplasms etiologically linked to viral factors. (genome.jp)
  • FDA approved treatment for Advanced Hepatocellular cancer. (bioportfolio.com)
  • Hepatocellular carcinoma (HCC) is a highly invasive cancer associated with high mortality rates. (bioportfolio.com)
  • Hepatocellular carcinoma (HCC) is the leading threat of cancer-related death in humans. (doaj.org)
  • Currently, sorafenib and lenvatinib, two multi-kinase inhibitors with potent anti-angiogenic capacity, are first-line therapy for hepatocellular carcinoma (HCC) that accounts for 80% of primary liver cancer ( 6 , 7 ). (frontiersin.org)
  • Dana-Farber/Brigham and Women's Cancer Center includes some of the world's top researchers and clinicians in hepatocellular carcinoma, the most common type of primary liver cancer. (dana-farber.org)
  • Hepatocellular Carcinoma (HCC) is worldwide the fifth most common cancer in men and represents the third most frequent cause of cancer death. (omicsonline.org)
  • Hepatocellular carcinoma (HCC) is a cancer of the liver , accounting for 80 - 90% of all liver cancer cases worldwide. (knowcancer.com)
  • Many people with hepatocellular carcinoma (HCC) have no symptoms until the disease becomes advanced. (upmc.com)
  • Approximately 3 to 5 percent of the population with cirrhosis is diagnosed with hepatocellular carcinoma each year, and about 80 percent of all people with hepatocellular carcinoma are cirrhotic. (microscopyu.com)
  • 2014. Trends in epidemiology, treatment, and survival of hepatocellular carcinoma patients between 1998 and 2009: an analysis of 1066 cases of a German HCC Registry. (unimedizin-mainz.de)
  • Reptilase test in cirrhosis and hepatocellular carcinoma. (bmj.com)
  • HCV infection causes acute hepatitis, chronic hepatitis, cirrhosis and hepatocellular carcinoma (HCC). (mdpi.com)
  • Here we show that knockdown of integrin subunits slows down the progression of hepatocellular carcinoma (HCC). (mit.edu)
  • Hepatitis B and/or C assist the progression of hepatocellular carcinoma because such hepatitides cause the body's immune system to attack the liver cells, some of which are undoubtedly infected by the hepatitis virus. (knowcancer.com)
  • The hepatocellular carcinoma (HCC) is one of the most common malignant tumors and carries a poor survival rate. (hindawi.com)
  • Hepatocellular carcinomas (HCC) are also known as primary liver cancers , hepatic tumors , or hepatomas . (upmc.com)
  • In particular, neither results in adequate control of hepatocellular carcinoma tumors larger than 3 cm. (medpagetoday.com)
  • Certain benign liver tumors, such as hepatocellular adenoma, may sometimes be associated with coexisting malignant HCC. (wikipedia.org)
  • Carcinomas are malignant tumors found both in humans and animals. (petmd.com)
  • 75% of its blood supply from the portal vein, hepatocellular tumors derive their blood supply nearly exclusively from the hepatic artery. (appliedradiology.com)
  • At NorthShore, we offer a full complement of leading-edge options for treating hepatocellular carcinoma. (northshore.org)
  • On November 9, 2018, the Food and Drug Administration granted accelerated approval to pembrolizumab (KEYTRUDA, Merck & Co., Inc.) for patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. (fda.gov)
  • Hepatocellular carcinoma (HCC) is also known as malignant hepatoma. (openpr.com)
  • Primary hepatocellular carcinoma (HCC), sometimes called hepatoma, is the most common form of primary liver malignancy 1 and is among the 10 most common tumours 2 in the world. (bmj.com)
  • The type species of the genus ORTHOHEPADNAVIRUS which causes human HEPATITIS B and is also apparently a causal agent in human HEPATOCELLULAR CARCINOMA. (bioportfolio.com)
  • Radiotherapy is not considered standard of care practice for patients for inoperable hepatocellular carcinoma despite the tumour's inherent radiosensitivity. (clinicaltrials.gov)
  • Conventional hepatocellular carcinoma is more frequently diagnosed in adults and is often seen in conjunction with underlying liver disease (for example, cirrhosis ). (childrenshospital.org)
  • Fibrolamellar hepatocellular carcinoma is a unique, rare entity apart from conventional hepatocellular carcinoma and requires novel and experienced approaches to care. (childrenshospital.org)
  • FHCC often does not produce alpha fetoprotein (AFP), a widely used marker for conventional hepatocellular carcinoma. (wikipedia.org)
  • Wang, X.-D. Non-Alcoholic Steatohepatitis and Hepatocellular Carcinoma: Implications for Lycopene Intervention. (mdpi.com)
  • Ip BC, Wang X-D. Non-Alcoholic Steatohepatitis and Hepatocellular Carcinoma: Implications for Lycopene Intervention. (mdpi.com)
  • Management of hepatocellular carcinoma (HCC) is best performed in a multidisciplinary setting. (medscape.com)
  • Another option is gene therapy, which although in its infancy at the present time, may have a significant role to play in the future management of hepatocellular carcinoma. (bmj.com)
  • Research is active in the area of pathogenesis and treatment of hepatocellular carcinoma. (nih.gov)
  • Surgical treatment of hepatocellular carcinoma: experience with liver resection and transplantation in 198 patients. (springer.com)
  • Which treatment is best for you will depend on the size and location of your hepatocellular carcinoma, how well your liver is functioning, and your overall health. (drugs.com)
  • Finally, on the basis of a patient-derived tumour xenograft mouse model of hepatocellular carcinoma, we found that treatment with avasimibe, an inhibitor of SOAT1, markedly reduced the size of tumours that had high levels of SOAT1 expression. (nature.com)
  • The 291 consecutive patients with hepatocellular carcinoma larger than 3 cm were randomly assigned to treatment with an emulsion of 50 mg of cisplatin (Platinol) and 10 mL of lipiodol (Lipiocis) followed by embolization with granules of gelatin sponge particles, with RF ablation at a temperature of 100 C, or with both. (medpagetoday.com)
  • The increase in incidences of hepatocellular carcinoma associated with hepatitis C virus are expected to grow the hepatocellular carcinoma treatment market during the forecast period. (openpr.com)
  • The advancement in technology, personalized medicine, cost effective treatment procedures are few other factors predicted to keep up the growth of global hepatocellular carcinoma treatment market. (openpr.com)
  • However, side effects associated with the chemotherapy, high cost of treatment are some of the major restraints limiting the growth of global hepatocellular carcinoma treatment market. (openpr.com)
  • The global hepatocellular carcinoma (HCC) treatment market has been segmented on the basis of application, end use and geography. (openpr.com)
  • Moreover, the increasing investment of pharmaceutical companies in the research and development of anticancer drugs would contribute to the growth of hepatocellular carcinoma treatment market. (openpr.com)
  • Bayer AG is one of the leading provider of hepatocellular carcinoma (HCC) treatment drugs. (openpr.com)
  • Some of the key players in hepatocellular carcinoma treatment market are Novartis Pharmaceuticals, Merck & Co., Inc., Bristol-Myers Squibb Company, AbbVie Inc., Johnson & Johnson Pvt. (openpr.com)
  • The risk of hepatocellular carcinoma in type 2 diabetics is greater (from 2.5 to 7.1 times the nondiabetic risk) depending on the duration of diabetes and treatment protocol. (wikipedia.org)
  • See also Hepatocellular Carcinoma Treatment Protocols . (medscape.com)
  • On Friday, the FDA approved Keytruda, an anti-PD-1 therapy, for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with the chemotherapy drug sorafenib. (biospace.com)
  • Zhu said the latest approval of Keytruda is important as it "provides a new treatment option for patients with hepatocellular carcinoma who have been previously treated with sorafenib. (biospace.com)
  • Sorafenib is a standard treatment for Hepatocellular Carcinoma. (bioportfolio.com)
  • The purpose of the study is to determine whether 4SC-201 alone or in combination with Sorafenib is effective and safe in the treatment of hepatocellular carcinoma in patients refractory to. (bioportfolio.com)
  • Advanced hepatocellular carcinoma (HCC) is a lethal malignancy with limited treatment options. (bioportfolio.com)
  • When it comes to hepatocellular carcinoma (HCC), doctors have a handful of treatment options at their disposal. (curetoday.com)
  • 2015. Treatment and survival of non-alcoholic steatohepatitis associated hepatocellular carcinoma. (unimedizin-mainz.de)
  • The purpose of the study was to evaluate the efficacy of enzalutamide in participants with advanced hepatocellular carcinoma (HCC) as measured by overall survival (OS). (pfizer.com)
  • Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib. (bioportfolio.com)
  • Fibrolamellar hepatocellular carcinoma (FHCC) is a rare form of hepatocellular carcinoma (HCC) that typically affects young adults and is characterized, under the microscope, by laminated fibrous layers interspersed between the tumour cells. (wikipedia.org)
  • The name fibrolamellar hepatocellular carcinoma was coined by Craig et al. (wikipedia.org)
  • 2016. https://www.unboundmedicine.com/washingtonmanual/view/Washington-Manual-of-Medical-Therapeutics/602671/5/Hepatocellular_Carcinoma. (unboundmedicine.com)
  • In addition, we found that variants within several drug targets such as KIT, SYK, and PIK3CA were mutated in a fully clonal manner, indicating their therapeutic potentials for hepatocellular carcinoma. (aacrjournals.org)
  • What Are the Signs & Symptoms of Hepatocellular Carcinoma (HCC)? (kidshealth.org)
  • Young adults afflicted by the rare fibrolamellar variant of hepatocellular carcinoma may have none of the typical risk factors, i.e. cirrhosis and hepatitis. (wikipedia.org)
  • Retrieved on June 25, 2019 from https://www.news-medical.net/health/What-are-Hepatocellular-Carcinomas.aspx. (news-medical.net)
  • 2019. What are Hepatocellular Carcinomas? . (news-medical.net)
  • On January 14, 2019, the Food and Drug Administration approved cabozantinib (CABOMETYX, Exelixis, Inc.) for patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. (fda.gov)
  • Latest advances in external beam radiotherapy for hepatocellulalar carcinoma. (slideshare.net)
  • In this paper, a summary of most relevant available data from published papers reporting various tissue and serum biomarkers involved in hepatocellular carcinoma was presented. (hindawi.com)
  • Understanding the intratumoral heterogeneity of hepatocellular carcinoma is instructive for developing personalized therapy and identifying molecular biomarkers. (aacrjournals.org)
  • An ORTHOHEPADNAVIRUS causing chronic liver disease and hepatocellular carcinoma in woodchucks. (bioportfolio.com)
  • An inverse association has been reported between coffee drinking and the risk of hepatocellular carcinoma (HCC) and chronic liver disease (CLD), but its magnitude is still unclear. (ingentaconnect.com)
  • US-born Hispanics are more likely to get hepatocellular carcinoma and to die from chronic liver disease compared with their foreign-born counterparts. (cancernetwork.com)
  • Hepatocellular carcinoma occurs most often in people with chronic liver diseases, such as cirrhosis caused by hepatitis B or hepatitis C infection. (drugs.com)
  • When diagnosed in children, hepatocellular carcinoma may be linked to hepatitis infection or genetic conditions. (childrenshospital.org)
  • Primary hepatocellular carcinoma is one of the 10 most common tumours, and the most common primary liver malignancy, in the world. (bmj.com)
  • 60 patients of radiological, biopsy proven advanced HCC (Hepatocellular carcinoma) patient will be randomized into two groups. (bioportfolio.com)
  • We present a patient with a 15 year history of genetic haemachromatosis who underwent resection of a hepatocellular carcinoma in a liver with normal architecture. (hindawi.com)
  • Liver resection for hepatocellular carcinoma. (nii.ac.jp)
  • Association between hepatocellular carcinoma (HCC)-related variables and metastasis stratified by total tumour volume (TTV). (medscape.com)
  • Hepatocellular carcinoma (HCC), hypervascular metastasis and hepatic adenoma. (appliedradiology.com)